

# Sinohealth Hldg 中康控股

## 中康控股有限公司

Sinohealth Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限公司)

Stock Code 股份代號: 2361

### 2024 INTERIM REPORT 中期報告





# Contents

## 目錄

<b>2</b>	Corporate Information	公司資料
<b>5</b>	Core Financial and Operational Data	核心財務及運營數據
<b>6</b>	Financial Summary	財務摘要
<b>7</b>	Management Discussion and Analysis	管理層討論及分析
<b>28</b>	Corporate Governance and Other Information	企業管治及其他資料
<b>40</b>	Unaudited Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	未經審核中期簡明綜合損益及其他全面收益表
<b>41</b>	Unaudited Interim Condensed Consolidated Statement of Financial Position	未經審核中期簡明綜合財務狀況表
<b>43</b>	Unaudited Interim Condensed Consolidated Statement of Changes in Equity	未經審核中期簡明綜合權益變動表
<b>45</b>	Unaudited Interim Condensed Consolidated Statement of Cash Flows	未經審核中期簡明綜合現金流量表
<b>48</b>	Notes to Unaudited Interim Condensed Consolidated Financial Information	未經審核中期簡明綜合財務資料附註
<b>82</b>	Definitions	釋義

## 2 CORPORATE INFORMATION 公司資料

### BOARD OF DIRECTORS

#### Executive Directors

Mr. Wu Yushu (*Chairman*)

Ms. Wang Lifang

#### Non-executive Director

Mr. Fu Haitao

#### Independent Non-executive Directors

Ms. Wang Danzhou

Ms. Du Yilin

Mr. Wei Bin

### AUDIT COMMITTEE

Mr. Wei Bin (*Chairman*)

Ms. Wang Danzhou

Ms. Du Yilin

### REMUNERATION COMMITTEE

Ms. Wang Danzhou (*Chairperson*)

Ms. Du Yilin

Ms. Wang Lifang

### NOMINATION COMMITTEE

Mr. Wu Yushu (*Chairman*)

Ms. Du Yilin

Ms. Wang Danzhou

### AUTHORISED REPRESENTATIVES

Mr. Wu Yushu

Ms. Zhang Xiao

### JOINT COMPANY SECRETARIES

Mr. Wan Chuan

(*resigned with effect from 10 September 2024*)

Ms. Zhang Xiao *ACG, HKACG*

### 董事會

#### 執行董事

吳鬱抒先生(*主席*)

王莉芳女士

#### 非執行董事

付海濤先生

#### 獨立非執行董事

王丹舟女士

杜依琳女士

魏斌先生

### 審核委員會

魏斌先生(*主席*)

王丹舟女士

杜依琳女士

### 薪酬委員會

王丹舟女士(*主席*)

杜依琳女士

王莉芳女士

### 提名委員會

吳鬱抒先生(*主席*)

杜依琳女士

王丹舟女士

### 授權代表

吳鬱抒先生

張瀟女士

### 聯席公司秘書

萬川先生

(*於2024年9月10日辭任*)

張瀟女士 *ACG, HKACG*

### REGISTERED OFFICE IN THE CAYMAN ISLANDS

89 Nexus Way  
Camana Bay  
Grand Cayman KY1-9009  
Cayman Islands

### PRINCIPAL PLACE OF BUSINESS IN THE PRC

Room 1111, No.5 Wangjiang Second Street  
Huangge Town, Nansha District  
Guangzhou City  
Guangdong Province  
PRC

### PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 732, 7th Floor, Rykadan Tower  
135 Hoi Bun Road, Kwun Tong  
Kowloon  
Hong Kong

### CAYMAN ISLANDS PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Ogier Global (Cayman) Limited  
89 Nexus Way  
Camana Bay  
Grand Cayman KY1-9009  
Cayman Islands

### HONG KONG SHARE REGISTRAR AND TRANSFER OFFICE

Boardroom Share Registrars (HK) Limited  
2103B, 21/F  
148 Electric Road  
North Point  
Hong Kong

### 開曼群島註冊辦事處

89 Nexus Way  
Camana Bay  
Grand Cayman KY1-9009  
Cayman Islands

### 中國主要營業地點

中國  
廣東省  
廣州市  
南沙區黃閣鎮  
望江二街5號1111房

### 香港主要營業地點

香港  
九龍  
觀塘海濱道135號  
宏基資本大廈7樓732室

### 開曼群島股份過戶登記總處

Ogier Global (Cayman) Limited  
89 Nexus Way  
Camana Bay  
Grand Cayman KY1-9009  
Cayman Islands

### 香港證券登記處

寶德隆證券登記有限公司  
香港  
北角  
電氣道148號  
21樓2103B室

## 4 CORPORATE INFORMATION 公司資料

### LEGAL ADVISERS

*As to Hong Kong law*  
Jingtian & Gongcheng LLP  
Suites 3203-3207  
32/F, Edinburgh Tower  
The Landmark  
15 Queen's Road Central  
Hong Kong

*As to PRC law*  
Jingtian & Gongcheng  
45/F, K.Wah Centre  
1010 Huaihai Road (M)  
Shanghai  
China

### AUDITOR

Ernst & Young  
*Certified Public Accountants*  
*Registered Public Interest Entity Auditor*  
27/F, One Taikoo Place  
979 King's Road  
Quarry Bay  
Hong Kong

### PRINCIPAL BANKS

Ping An Bank Guangzhou Huangpu Avenue Branch  
1/F, Fulilong Square  
No. 76 Huangpu Avenue West  
Tianhe District  
Guangzhou City  
Guangdong Province  
PRC

### STOCK CODE

2361

### COMPANY'S WEBSITE

[ir.sinohealth.cn](http://ir.sinohealth.cn)

### 法律顧問

*關於香港法例*  
競天公誠律師事務所  
香港  
皇后大道中 15 號  
置地廣場  
公爵大廈 32 樓  
3203-3207 室

*關於中國法律*  
競天公誠律師事務所  
中國  
上海市  
淮海中路 1010 號  
嘉華中心 45 層

### 核數師

安永會計師事務所  
*執業會計師*  
*註冊公眾利益實體核數師*  
香港  
鰂魚涌  
英皇道 979 號  
太古坊 1 座 27 樓

### 主要往來銀行

平安銀行廣州黃埔大道支行  
中國  
廣東省  
廣州市  
天河區  
黃埔大道西 76 號  
富力盈隆廣場首層

### 股票代碼

2361

### 公司網址


[ir.sinohealth.cn](http://ir.sinohealth.cn)

# CORE FINANCIAL AND OPERATIONAL DATA


## 核心財務及運營數據

5

### Financial performance 財務表現



### BUSINESS SEGMENT FINANCIAL PERFORMANCE 業務板塊財務表現



### Core competence 核心競爭力

#### Industrial Partnering Network 產業合作網絡

Medical retail partnering network: the number of partnering pharmacy stores exceeded 160,000 spanning 30 provinces/349 cities, the number of pharmacy stores using the SIC system exceeded 110,000.  
 醫藥零售合作網絡：合作藥店門店數累計超過16萬家，分佈30個省/349個地市，使用SIC系統藥店門店數累計超過11萬家。

Health management partnering network: it reached over 160 hospitals and 650 physical examination centers. The number of users who obtained the interpretation of physical medical reports exceeded 4.345 million, and the maximum daily processing volume of physical medical report interpretation through AI-MDT system exceeded 40,000 cases, an increase of approximately 448% over the same period in 2023.  
 健康管理合作網絡：觸達逾160家醫院以及650家體檢中心，獲取體檢報告解讀的用戶數累計超過434.5萬名，AI-MDT系統體檢報告解讀的日最高處理量超過4萬例，較2023年同期增長約448%。

Patient management services: the number of partnering hospitals exceeded 300, serving more than 250,000 patients.  
 患者管理服務：合作醫院數超過300家，服務患者超過25萬名。

iMDT platform: the number of registered oncologists exceeded 13,000, organizing more than 500 MDT conferences, and connecting more than 120,000 doctors.  
 iMDT平臺：註冊腫瘤醫生數累積超過1.3萬名，組織MDT診療會議超過500場，連接醫生數超過12萬名。

#### Big Data Processing Technology 大數據處理技術

##### Data Processing and Analysis Capacity 數據處理及分析能力

Establish a standardized and structured master data base, including 38 health industry master data base, covering pharmaceutical retail, industry supervision, medicine, pharmacy and life sciences.  
 建立標準化、結構化的主資料庫，包括38個健康行業主資料庫，涵蓋醫藥零售、行業監管、醫學、藥學和生命科學領域。

Data processing capacity greatly improves, machine automatic cleaning rate exceeds 97%, accuracy rate exceeds 99% and maximum response speed reaches T+1.  
 數據處理能力極大提升，機器自動清洗率超過97%，準確率超過99%，最快回應速度達到T+1。

##### Data Value Mining Ability 數據價值挖掘能力

"Woodpecker" smart health management and medical middleware: its medical knowledge graph gathers the consensus of more than 300 experts across 16 disciplines, covers 31 disease types, 1,770 diseases and 801 individual indicators and 10 disease risk assessment models.  
 "車鵲鳥"智慧健康管理與醫療中臺：超16個學科，300+專家共識，構建了涵蓋31個病種、1,770種疾病、801個單指標的醫學知識圖譜，10大疾病風險評估模型。

The data science models of "Tiangong No.1" commercial data smart middleware are applied in five fields, such as product operation, drug sales, market and public opinion monitoring and consumer behavior analysis.  
 "天宮一號"商用數據智能中臺的數據科學模型應用於產品運營、藥品銷售、市場及輿情監測、消費者行為分析等五大應用領域。

#### Industrial Ecological Platform 產業生態平臺

The Group has established a portfolio of healthcare industry conferences/exhibition events and media services to build a valuable ecological chain for industry participants. It is also the main scene of the Group's product marketing and "traffic monetisation".  
 本集團搭建的健康產業會議/會展活動和媒介服務組合，為行業參與者構建價值生態鏈，同時也是本集團產品行銷及"流量變現"的主要場景。

CPEO held successfully for 17 sessions, has become a forward-looking industry conference with leading position in China's healthcare industry in terms of specifications, scale and influence. There were 8,000 official participants and more than 60,000 participants, reaching a new high in scale.  
 西普會已成功舉辦十七屆，發展成為中國健康產業規格領先、規模領先、影響力領先的前瞻性產業會議，正式參會嘉賓8,000人，參會人數超6萬人，規模再創新高。

Industrial Ecological Platform had reached to a total of nearly one million industry professionals.  
 產業生態平臺觸達行業專業人士合計近百萬。

### Talent Team and Data Security 人才團隊及數據安全

#### Industrial Partnering Network 產業合作網絡

Professional talent reserve: 39% of employees have medical and pharmaceutical background and experience, 17% have artificial intelligence and computer science background and experience; 346 solution and product personnel, accounting for 44%, and 214 R & D personnel, accounting for 28%.  
 專業人才儲備：擁有醫學和醫藥背景和經驗的員工佔比39%，擁有人工智能和計算機科學的背景和經驗員工佔比17%；解決方案及產品人員346名，佔比44%，研發人員214名，佔比28%。

The Company was recognized as the Guangdong Big Health Pharmaceutical Data Engineering Technology Research Center by the Guangdong Engineering Technical Research Center.  
 獲廣東省工程技術研究中心認定為廣東省大健康醫藥數據工程技術研究中心。

## 6 FINANCIAL SUMMARY

### 財務摘要

		For the six months ended 30 June 截至 6 月 30 日止六個月		Year-on-year change
		2024 (Unaudited) 2024 年 (未經審核) RMB'000 人民幣千元	2023 (Unaudited) 2023 年 (未經審核) RMB'000 人民幣千元	同比變動
<b>Revenue</b>	<b>收入</b>	<b>159,531</b>	144,950	10.1%
Smart Decision Cloud	智慧決策雲	<b>68,233</b>	72,073	-5.3%
Smart Retail Cloud	智慧零售雲	<b>56,437</b>	43,834	28.8%
Smart Medical Cloud	智慧醫療雲	<b>17,967</b>	23,314	-22.9%
Smart Health Management Cloud	智慧健康管理雲	<b>16,894</b>	5,729	194.9%
<b>Cost of sales</b>	<b>銷售成本</b>	<b>70,743</b>	69,768	1.4%
<b>Gross profit</b>	<b>毛利</b>	<b>88,788</b>	75,182	18.1%
<b>Operating profit *</b>	<b>經營利潤 *</b>	<b>20,035</b>	12,362	62.1%
<b>Net profit</b>	<b>淨利潤</b>			
<b>(excluding exchange gains and losses)</b>	<b>(不包含匯兌損益)</b>	<b>40,057</b>	32,525	23.2%
<b>Net profit margin</b>	<b>淨利潤率</b>			
<b>(excluding exchange gains and losses)</b>	<b>(不包含匯兌損益)</b>	<b>25.1%</b>	22.4%	2.7%
<b>Net profit</b>	<b>淨利潤</b>	<b>42,348</b>	46,970	-9.8%

\* "Operating profit" is defined as gross profit less (i) selling and distribution expenses, (ii) administrative expenses, (iii) research and development costs, and (iv) impairment losses on financial assets, net.

\* 「經營利潤」定義為毛利扣減(i)銷售及分銷開支，(ii)行政開支，(iii)研發成本，及(iv)金融資產減值虧損淨額。

## BUSINESS REVIEW

Relying on industry-leading data assets, AI algorithm models, rich industry experience and professional insight, the Group has continuously enriched the types of products and services with the help of technological innovation and the ability to transform scientific and technological achievements, providing customers with one-stop products and services of “SaaS+ professional service + industry ecological platform”. The Group has efficiently empowered customers in terms of digital transformation, market expansion, client management and decision making, enabling them to enhance efficient operational decision making and targeted market connection as two core capabilities to improve their operating efficiency and achieve performance growth.

During the Reporting Period, the Group’s revenue scale and operating efficiency improved further, benefiting from the continuous development of industrial cooperation networks and the continuous innovation of products and services, the number of customers of and price of Smart Retail Cloud and SaaS products have risen simultaneously. The operating income was approximately RMB159.5 million, representing a year-on-year increase of approximately 10.1%; The leading big data processing technology and the continuous consolidation of the data platform construction have greatly improved the technical efficiency, thus promoting the continuous optimization of the Group’s cost efficiency and breeding a higher-quality group profit model, the operating profit increased approximately 62.1% year-on-year. Excluding the impact of exchange gains and losses, the net profit was approximately RMB40.1 million, representing a year-on-year increase of approximately 23.2%, and the net profit margin (excluding exchange gains and losses) increased 2.7 percentage points compared with the corresponding period of 2023. Our customer range has covered major players in the health industry such as pharmaceutical and medical device manufacturers, pharmaceutical and medical device retailers, physical examination institutions, medical institutions, and innovative pharmaceutical enterprises. We had 869 corporate customers, increased by 3.2% from 842 corporate customers in the corresponding period of 2023, among them, the repurchase sales rate of leading pharmaceutical and medical device corporate customers was 99.7%, increased by 5 percentage points as compared with the corresponding period of 2023.

## 業務回顧

本集團依託行業領先的數據資產、AI算法模型、豐富的行業經驗以及專業洞察能力，借助技術創新及科技成果轉化能力，不斷豐富產品和服務種類，為客戶提供「SaaS+專業服務+產業生態平台」的一站式產品及服務，在數字化轉型、市場開拓、客戶管理、決策運營等方面高效賦能客戶，助力客戶提升高效經營決策和精準市場連接兩項核心能力，提升客戶經營效率和實現業績增長。

報告期內，受益於產業合作網絡的持續開拓、產品與業務的不斷創新，智慧零售雲和SaaS產品的客戶量價齊升，從而帶動本集團的營收規模和經營效益得到進一步提升，營業收入為約人民幣159.5百萬元，同比增長約10.1%；領先的大數據處理技術與不斷夯實的數據平台建設，帶來技術效率的極大提升，從而推動集團成本效率持續優化，孕育出更高質量的集團盈利模型，經營利潤同比增長約62.1%，剔除匯兌損益影響，淨利潤金額為約人民幣40.1百萬元，同比增長約23.2%，淨利潤率（不包含匯兌損益）較2023年同期增長2.7個百分點。我們的客戶範圍已覆蓋藥械生產商、藥械零售、體檢機構、醫療機構、創新藥企等健康產業主要參與群體，企業級客戶數量為869家，較2023年同期的842家增長3.2%，其中，頂尖製藥及醫療設備企業客戶的復購銷售率為99.7%，較2023年同期提升5個百分點。



## 8 MANAGEMENT DISCUSSION AND ANALYSIS

### 管理層討論及分析

#### SMART DECISION CLOUD

Smart Decision Cloud products are mainly designated for medical product suppliers, connecting the main scenarios of research and development, production, distribution, marketing and end-user retailing of medical device products with industry data as the core, providing pharmaceutical and medical equipment enterprises with an integrated smart decision cloud solution that enables customers to establish efficient decision-making capability and improve decision-making efficiency. It has maintained a leading position in terms of market size and recorded sustainable growth.

As at 30 June 2024, our revenue from Smart Decision Cloud was approximately RMB68.2 million, with 412 corporate customers purchasing the Group's Smart Decision Cloud services. The overall repurchase sales rate for corporate customers increased approximately 0.8 percentage points year-on-year as customers' willingness to repurchase continued to increase. Among them, CHIS, one of our main SaaS products, achieved good market performance, with approximately 36% year-on-year increase in the number of corporate customers and approximately 9% year-on-year increase in the unit price of customers.

We built the Sinohealth digital decision service and product system of "3 big data × 3 big services + digital insight SaaS system", and collected 3 big data types: 1) medical consumption market data including retail, county, new retail, DTP and other scenarios; 2) consumer portrait data, including consumer drug purchasing behavior database and consumer drug purchasing mind database; and 3) retail terminal data, including drug sales potential data and pharmacy characteristics big data. Through intelligent modeling, we conducted interactive and multi-angle analysis of the 3 types of big data and provided customers with three categories of insight consulting services: 1) drug market insight service; 2) consumer research insight service; and 3) terminal accurate strategy information service, to empower multiple scenarios,

#### 智慧決策雲

智慧決策雲的產品主要面向醫療產品供應商，以行業數據為核心連接藥械產品研發、生產、流通、推廣、終端零售的等主要場景，為製藥及醫療設備企業提供數字化綜合解決方案，助力客戶建立高效決策能力，提高決策效率。本項業務的市場規模已經處於領先地位並持續增長。

截至2024年6月30日，智慧決策雲的收入為約人民幣68.2百萬元，有412家企業級客戶購買本集團的智慧決策雲服務，企業級客戶整體複購銷售率同比提高約0.8個百分點，客戶複購支付意願持續提升。其中，我們的主要SaaS產品之一「開思系統」獲得較好的市場表現，企業級客戶數量同比上升約36%，客單價同比上升約9%。

我們搭建了「3大數據×3大服務+數字洞察SaaS系統」的中康數字決策服務與產品體系，彙集了3大數據種類：1)包含零售、縣域、新零售、DTP藥房等場景的醫藥消費市場數據，2)包含消費者購藥行為數據庫和消費者購藥心智數據庫的消費者畫像數據，以及3)包含藥品銷售潛力數據和藥店特徵大數據的零售終端數據；我們通過智能建模對3大數據進行交互和多角度分析，為客戶提供3大類洞察諮詢服務，包括：1)藥品市場洞察服務，2)消費者研究洞察服務，和3)終端精準策略信息服務，實現覆蓋「人」、「貨」、「場」的多角度場景賦能；同時，我們還為客戶提供以數據洞察驅動的決策一體化SaaS系統，幫助客戶對市場數據進行

covering “people”, “goods” and “venue”. Meanwhile, we provided our customers with an integrated SaaS system for decision making driven by data insight, and helped them intelligently and visually manage market data, conduct governance analysis on internal data and interact with market data, and support the decision-making of production and marketing, market layout and drug research and development with data insight results.

Our platform events, like CPEO, CPE, the Healthcare Industry Capital Summit and the Traditional Chinese Medicine Ecological Conference, gathered health industry key elites, and carried out multi-level and multidimensional data release covering topics from the prediction and analysis of the development trend of health production ecology, to the exploration of paths in various branches, which provided customers with forward-looking, systematic exchange of ideas and information, strategic integration and precise interaction of diverse resources, so as to further improve the interconnection efficiency between industries and promote resources optimal allocation. Up to the date of this report, CPEO has been successfully held for 17 sessions and has developed into a forward-looking industry conference with leading specifications, scale and influence in the Chinese health industry. More than 8,000 decision-making elites from government agencies, domestic and foreign mainstream brand industries, innovative drug enterprises and innovative drug technology companies, mainstream pharmaceutical businesses, retail enterprises, domestic and foreign capital institutions, digital technology companies, commercial insurance institutions, medical and health service institutions as representatives attended the meeting, with the total number of participants exceeding 60,000.

智能化和可視化管理，對內部數據開展治理分析並與市場數據進行交互，以數據洞察結果支持生產營銷、市場佈局和藥物研發的決策。

我們舉辦的西普會、西派會、健康產業資本峰會、中醫藥生態大會等平台活動集聚健康產業主要精英群體，從健康產業生態發展趨勢預判與分析到各分支領域路徑探索，展開多層次、立體化數據發佈，為健康產業各主體提供前瞻性、系統性的思想與信息交流、從策略到戰略的多元資源對接和精準交互，進一步提高產業間互通互聯效率，促進資源優化配置。截至本報告發佈日，西普會已成功舉辦十七屆，發展成為中國健康產業規格領先、規模領先、影響力領先的前瞻性產業會議，來自政府機構、國內外主流品牌工業、創新藥企業及創新藥技術公司、主流醫藥商業、零售企業、國內外資本機構、數字技術公司、商業保險機構、醫療及健康服務機構等決策精英參會代表超8,000名，參會人數超6萬人。

## 10 MANAGEMENT DISCUSSION AND ANALYSIS

### 管理層討論及分析

#### SMART RETAIL CLOUD

After iterative upgrading, we integrated digital functions such as member management, category management, intelligent marketing, chronic disease management, and pharmaceutical services with SIC as the core system, to help pharmacies achieve functional upgrading, create a “patient-centered” personal health management portal, and improve the membership loyalty and consumption willingness of our cooperative pharmacies. As at 30 June 2024, the Group has established cooperation with more than 2,900 pharmaceutical retail enterprises and more than 160,000 pharmacy stores, maintaining a leading position in the market. Our digital cooperation with pharmacies also facilitated instant communication and feedback processes for drug retail data, empowering the Group’s overall business. Leveraging on the unique advantages of SIC, the Group has established a “one-stop” data centralized analysis capability, data-driven marketing solution capability and digital precision marketing capability under the pharmacy consumption scenario, aiming to attract more pharmaceutical and medical equipment enterprises and pharmaceutical retail enterprises to join our business expansion plan.

As of 30 June 2024, 519 corporate customers purchased our Smart Retail Cloud service, representing an increase of approximately 17.2% compared with the corresponding period of 2023, including 19 new corporate customers. The overall repurchase sales rate for corporate customers was approximately 78.8%. During the Reporting Period, our revenue from Smart Retail Cloud services increased approximately 28.8% to approximately RMB56.4 million from approximately RMB43.8 million for the corresponding period of 2023. The repurchase unit price for corporate customers increased approximately 22.5% year-on-year.

#### 智慧零售雲

經過迭代升級，我們以SIC為核心系統集成了會員管理、品類管理、智能營銷、慢病管理、藥事服務等數字化功能，助力藥店實現功能升級，打造「以患者為中心」的個人健康管理入口，提高我們合作藥店的會員忠誠度及消費意願，截至2024年6月30日，本集團已經與累計超過2,900家的醫藥零售企業、累計超過16萬家的藥店門店建立合作，穩居市場領先地位。我們和藥店的數字化合作也促進了雙方的實時溝通及藥品零售數據的反饋流程，為本集團整體業務賦能。利用SIC的獨特優勢，本集團在藥店消費場景下，建立了「一站式」數據集中分析能力、數據驅動營銷解決方案能力和數字化精準營銷能力，致力於吸引更多的製藥及醫療設備企業和醫藥零售企業加入我們的業務拓展計劃。

截至2024年6月30日，有519家企業級客戶購買本集團的智慧零售雲服務，較2023年同期增長約17.2%，其中新增企業級大客戶19家。企業級客戶整體複購銷售率約為78.8%。報告期內，智慧零售雲的收入同比增長約28.8%，由2023年同期的約人民幣43.8百萬元增加至約人民幣56.4百萬元，企業級客戶複購客單價同比提升約22.5%。

## MANAGEMENT DISCUSSION AND ANALYSIS 11

### 管理層討論及分析

We utilized big data to deeply analyse pharmacy stores and patients' demands, preference and behavior, provided customers with a wide range of products portfolio and professional services including data-driven marketing solutions, digital precision marketing plans and professional training, and strengthened the in-depth interaction between medical product suppliers and pharmacies, and between pharmacies and patients, so that our customers could effectively and accurately access to the target groups, and help patients improve their awareness and trust in pharmaceutical products, accurately improving the treatment effect and the healthy living standard and quality of life of patients; we helped customers quantitatively evaluate the input-output ratio of marketing programs through data insights, thereby optimizing the sales expense structure, improving the refined management level of sales costs, and enhancing customers' market share and marketing profitability.

Meanwhile, through industry ecological platform, we also held PHCF, MASC and other industry events, and strived to promote the commodity trading and high-quality development of the health industry through panoramic data analysis, policy trends interpretation, health consumption new trends interpretation and product display, etc.

#### SMART HEALTH MANAGEMENT CLOUD

We provide physical examination users and chronic disease patients with Woodpecker AI-MDT health management platform and supporting health management services through medical institutions and health management institutions. The Woodpecker AI-MDT system gathers the consensus of more than 300 experts from Tertiary Hospitals across 16 disciplines, which on the basis of professional medical guidance, constructs the medical knowledge graph covering 31 disease types, 1,770 diseases and 801 individual indicators. Through AI technology and 10 major disease risk assessment models, the Woodpecker AI-MDT system makes a comprehensive analysis of physical examination data and provides users

我們利用大數據深度分析藥店和患者的需求、偏好及行為，向客戶提供數據驅動營銷解決方案、數字精準營銷方案和專業培訓等多種組合產品和專業服務，加強醫療產品供應商與藥店之間、藥店與患者之間的深度互動，讓我們的客戶有效精準地接觸目標受眾，幫助患者提高對醫藥產品的認知度和信任度，精準提高治療效果，提升患者的健康生活水平和生活質量；我們通過數據洞察，幫助客戶量化評估營銷方案的投入產出比，從而優化銷售費用結構，提高銷售成本精細化管理水平，提升客戶的市場份額和市場營銷收益。

同時，我們亦通過產業生態平台，組織西鼎會、美思會等產業活動，通過全景數據分析、解讀政策趨勢、解讀健康消費新趨勢和產品展示等內容，致力於推動健康產業商品交易，促進產業實現高質量發展。

#### 智慧健康管理雲

我們通過醫療機構與健康管理機構，為體檢用戶和不同疾病的慢病人群提供卓睦鳥健康管理AI-MDT及配套的健康管理服务。卓睦鳥健康管理AI-MDT系統彙集了16個學科的超過300名三甲醫院專家的共識，結合專業醫學指南，構建了涵蓋31個病種、1,770種疾病、801個單指標的醫學知識圖譜。卓睦鳥健康管理AI-MDT系統通過AI技術和10大疾病風險評估模型，對體檢數據進行綜合分析，為用戶提供包含醫療、體檢、飲食和運動的個性化健康管理方案。區別於傳統體檢報告，AI-MDT致力於為體檢用戶提供更系統化、更詳細、更全面的專

## 12 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

with personalized health management solutions including medical treatment, physical examination, diet and exercise. Unlike traditional physical examination reports, AI-MDT is committed to providing physical examination users with more systematic, more detailed and more comprehensive expert consultation physical examination reports. We established a relatively comprehensive health management system in the post-examination stage focusing on the needs of patients, equipped with health management and single-type chronic disease digital therapy modules and SCRM member management functions, which can meet the health management requirements of patients for the whole process after examination through early warning and monitoring, chronic disease management, drug purchasing, re-examination and continuous evaluation, and meanwhile help physical examination centers build a digital health management service system to improve health management service capacity and income-increasing capacity.

Benefiting from its mature technology and differentiated advantages, AI-MDT has been unanimously recognised by cooperative customers and physical examination users. At present, this business has begun to take shape and has reached approximately 160 hospitals and 650 private physical examination centers. As at 30 June 2024, over 4.345 million users obtained physical examination interpretations, representing an increase of approximately 4.04 million as compared with the corresponding period of 2023, and the maximum daily processing volume of the AI-MDT system for the interpretation of physical examination reports exceeded 40,000 cases, representing an increase of approximately 448% as compared with the corresponding period of 2023.

In terms of severe illness, we are closely connected with tumor experts and doctors at different levels of hospitals based on the intelligent iMDT platform and professional operation capability, providing tumor patients with more authoritative diagnosis and treatment service plans and health management plans that promote patients to receive more matching drugs, treatments and health management services.

家會診體檢報告。我們圍繞患者需求建立了更完備的健康管理體系，搭載了健康管理和單病種慢病數字療法模塊和SCRM會員管理功能，可以通過預警監控、慢病管理、藥品購買、複檢、持續評估等方式滿足患者檢後的全流程健康管理需求，同時幫助體檢中心構建數字化健康管理服務體系，提升健管服務能力和增收能力。

得益於成熟技術和差異化優勢，AI-MDT得到合作客戶和體檢用戶的一致認可。目前該業務已初具市場規模，觸達了約160家醫院和650家民營體檢中心。截至2024年6月30日，獲取體檢報告解讀的用戶數量已累計超過434.5萬名，較2023年同期增長約404萬名，AI-MDT系統體檢報告解讀的日最高處理量超過4萬例，較2023年同期增長約448%。

在重疾方面，我們基於智能化iMDT平台及專業運營能力，緊密連接不同等級醫院的腫瘤領域專家、醫生，為腫瘤患者提供更權威的診療服務方案與健康管理方案，促進患者接受匹配度更高的藥物、治療和健康管理服務。

## MANAGEMENT DISCUSSION AND ANALYSIS

### 管理層討論及分析

As at 30 June 2024, the number of registered oncologists on the iMDT platform has accumulated more than 13,000, more than 500 MDT diagnosis and treatment meetings have been organized, and the number of connected doctors has exceeded 120,000. The tumor types currently cover colorectal cancer, lung cancer, stomach cancer, liver cancer, brain glioma, colorectal cancer and breast cancer. The Group further expands the types and improve the quality of data through case collection and data analysis to better serve medical institutions, doctors and pharmaceutical companies in the application of tumor drugs, doctor-patient education and drug research and development.

#### SMART MEDICAL CLOUD

Smart Medical Cloud business segment is committed to connecting major participants of medical value chain, co-building the closed ecology, providing medical device enterprises, medical institutions and other participants in medical industry with patient management comprehensive solution and research efficiency improvement plan. Benefiting from technological upgrading and market development, our Smart Medical Cloud achieved an operating revenue of approximately RMB18.0 million during the Reporting Period. The repurchase sales rate of corporate customers reached 100.0%, representing a year-on-year increase of approximately 13.5 percentage points, as customer repurchase intentions continued to increase.

The Smart Medical Cloud business segment focuses on medical scenarios, with major businesses including patient management service and research SaaS platform etc. The Group integrates six main functions, namely medical services, pharmaceutical services, psychological support, remote intelligent testing, financial assistance and home care, works with medical device enterprises and medical institutions to provide more digital therapies in the whole medical management process combining with service solutions

截至2024年6月30日，iMDT平台註冊腫瘤醫生數量已累積超過1.3萬名，累計組織召開的MDT診療會議超過500場、連接醫生數量超過12萬名。目前已經覆蓋的腫瘤類型包括：結直腸癌、肺癌、胃癌、肝癌、腦膠質瘤、結直腸癌、乳腺癌等主要高發病率腫瘤類型，通過案例收集和數據分析，本集團得以進一步擴展數據種類和提高數據質量，可以為醫療機構、醫生和藥企在腫瘤治療藥物應用、醫患教育和藥品研發等方面提供更好的服務。

#### 智慧醫療雲

智慧醫療雲業務板塊致力於打通醫療價值鏈上的主要參與者，共同構建閉環生態，為藥械企業、醫療機構及醫療行業的其他參與者提供患者管理綜合解決方案以及科研效率提升方案。得益於技術升級和市場拓展，智慧醫療雲在報告期內實現營業收入約人民幣18.0百萬元，企業級客戶整體複購銷售率為100.0%，同比上升約13.5個百分點，客戶複購意願持續提升。

智慧醫療雲板塊聚焦醫療場景，主要業務包括患者管理服務和科研SaaS平台等。本集團將醫療服務、藥事服務、心理支持、遠程智能檢測、經濟援助和居家護理六項主要功能融為一體，與藥械企業和醫療機構共同合作提供更多全病程管理數字療法+私域患者服務方案，創新性地提供了全程患者關護服務模式，這種服務模式有效地提高了患者在治療過程的連續性、便利性和專業性，同時也幫助藥械企業和

## 14 MANAGEMENT DISCUSSION AND ANALYSIS

### 管理層討論及分析

for patients in private domain, and creatively provides full process patient care service model that effectively increases the continuity, convenience and professionalism of patients in medical treatment process, and meanwhile helps medical device enterprises and medical institutions improve the patient management process, which has been highly recognised by customers. The research SaaS platform covers the full process of scientific research, from topic choice, literature search to paper draft, which is on the basis of deep learning and multi-modal large language models, and increases the scientific research efficiency of doctors.

### THREE CORE COMPETENCES

As a pioneer in the digitalisation of the healthcare industry, the Group possesses cutting-edge innovative technologies and profound data insights. Leveraging on its industry-leading industrial cooperation network, technical capabilities and industrial insight ability, the Group continues to improve its product quality and professional service capabilities, as well as increase its market share, enhance the cooperation with its key customers and expand its product portfolio and business scale, so as to contribute to the long-term sustainable development of the healthcare industry. We have established three core competences in terms of extensive industrial cooperation network, leading big data processing technology and ecological industrial platform.

1) Industrial cooperation network. We focus on scenarios such as pharmaceutical retail, physical examination, clinical diagnosis and treatment, and have established a broad and solid industrial cooperative network by comprehensive digital networks covering “doctor, medicine, patient”. As at 30 June 2024, our pharmaceutical retail cooperation network has covered more than 160,000 pharmacy stores spanning 349 cities and 30 provinces, among which the number of cooperative pharmacy stores using SIC system has exceeded 110,000. There are about 160 hospitals and 650 examination centers that have joined in our health management and cooperative network. We have cooperated with more than 300 hospitals through

醫療機構改善患者管理流程，得到客戶的高度認可；科研SaaS平台覆蓋了從選題、文獻檢索到論文草擬的科研全流程，基於深度學習與多模態大語言模型，提高醫生的科研效率。

### 三大核心競爭力

作為健康產業數字化的先行者，本集團具備前沿的創新技術及深刻數據洞察，憑藉行業領先的產業合作網絡、技術能力和產業洞察能力，不斷提升產品力和專業服務能力，擴大市場份額，提升與關鍵客戶的合作層次、產品種類和業務規模，為健康產業的可持續發展提供長效助力。我們已經建立廣泛的產業合作網絡、領先的大數據處理技術和生態化的產業平台三大核心競爭力。

1) 產業合作網絡。我們專注於醫藥零售、健康體檢、臨床診斷及治療等場景，通過覆蓋「醫、藥、患」的全面數字網絡，構建了廣泛而牢固的產業合作網絡。截至2024年6月30日，我們的醫藥零售合作網絡已經覆蓋藥店門店數累計超過16萬家，分佈30個省及349個地市，其中使用SIC系統的合作藥店門店數累計超過11萬家；我們的健康管理合作網絡已經觸達約160家醫院以及650家體檢中心；我們通過患者管理服務已與超過300家醫院開展合作，服務超過25萬名患者；iMDT平台註冊腫瘤醫生數量已累積超過1.3萬名，持續運營著中華結直腸癌MDT聯盟、南方腦膠質瘤

patient management services, serving more than 250,000 patients. The number of registered users of oncologists on the iMDT platform has accumulated more than 13,000. It has continued to operate six tumor specific MDT doctor alliances: China Colorectal Cancer MDT Alliance; Southern Brain Glioma MDT Alliance; Eastern Gastrointestinal Cancer MDT Alliance; Mammary Gland MDT Cloud Academy; Liver Cancer MDT Specialized Organization; and Lung Cancer MDT Specialized Organization.

- 2) Big data processing technology. Our core platform for data processing has data processing and analysis capabilities, which allows us to discover correlations and patterns between raw data, cultivating insights and professional knowledge. Through data governance, analysis, interpretation and prediction, we provide industry participants with SaaS products and professional services. In terms of basic capabilities, we make technical constructions in two aspects: (i) we focus on big data processing and analysis, artificial intelligence and cloud computing. On this basis, we established Sinohealth's standardised and structured master database, including 38 master databases of the health industry covering pharmaceutical retail, industry supervision, medicine, pharmacy and life sciences, building a complete master data labeling system, forming a knowledge graph of mutual mapping between data, so as to create a unified set of medical health data structured standards. Under the construction of such basic capabilities, our data processing capacity has great improvements, machine automatic cleaning rate exceeds 97%, accuracy rate exceeds 99%, and the fastest response speed reaches T+1; (ii) for the two different lines of medicine and medical care, we have established the "Tiangong No. 1" commercial data smart middleware + "Woodpecker" smart health management and medical middleware. Empowered by the dual middlewares, our data mining capacity has been improved. With our professional knowledge, artificial intelligence models and data insight capabilities, we provide customers with standardised SaaS products, customised professional services and overall solutions for various operational scenarios.

MDT聯盟、東方胃腸腫瘤MDT聯盟、乳腺MDT雲學苑、肝癌MDT專病組織、肺癌MDT專病組織六個腫瘤專病MDT醫生聯盟。

- 2) 大數據處理技術。我們的數據處理核心平台具備數據處理和分析能力，令我們發現原始數據之間的相關性和影響模式，並培養洞察力和專業知識，通過對數據的治理、分析、解讀和預測，為產業參與者提供SaaS產品和專業服務。在基礎能力方面，我們做了兩方面的技術建設：(i)我們專注於大數據處理及分析、人工智能、雲計算。在此基礎上，建立了標準化、結構化的中康主數據庫，包括38個涵蓋醫藥零售、行業監管、醫學、藥學和生命科學在內的健康行業主數據庫，構建完整的主數據標籤體系，形成數據之間的相互映射的知識圖譜，從而打造了一套統一的醫療健康數據結構化標準。在這個基礎能力建設下，我們數據處理能力得到很大的提升，機器自動清洗率超過97%，準確率超過99%，最快響應速度達到T+1；(ii)針對醫藥和醫療兩個不同的線條，我們建立了「天宮一號」商用數據智能中台+「卓睦鳥」智慧健康管理與醫療中台。雙中台的賦能，提升了我們數據價值的挖掘能力，我們憑藉專業知識、人工智能模型和數據洞察能力，針對各類運營場景，為客戶提供標準化的SaaS產品、定制化的專業服務以及整體解決方案。



## 16 MANAGEMENT DISCUSSION AND ANALYSIS

### 管理層討論及分析

3) Ecological industrial platform. We have established a leading portfolio of healthcare industry conferences/exhibition events and media services to build a valuable ecological chain for industry participants. This platform was also a key product marketing scenario for the Group's industrial customers, enabling the Group to conduct in-depth business negotiations with customers, which improved marketing efficiency and reduced marketing costs. CPEO that we held successfully for 17 sessions has become a forward-looking industry conference with leading position in China's healthcare industry in terms of specifications, scale and influence, providing forward-looking and systematic exchanges of ideas and information for the industry and realising the strategic integration, cooperation and interaction of diversified resources. In addition, our ecological industrial platform has reached nearly one million professionals including pharmaceutical retail experts, pharmaceutical and medical device manufacturers, pharmacists, physicians, medical experts, industry investors and others.

### FUTURE OUTLOOK

According to the *Digital China Development Report (2023)*, the added value of the core industries in the digital economy was estimated to exceed RMB12 trillion in 2023, accounting for approximately 10% of the GDP. The revenue from emerging businesses such as cloud computing and big data has increased steadily, with an increase of 37.5% compared to last year. In recent years, a new round of information technologies represented by big data, cloud computing and artificial intelligence has developed rapidly, which has promoted the vigorous development of China's digital economy. In the context of the "Data Elements ×" Three-Year Action Plan actively promoted by China, the Group will fully leverage its core strengths such as data governance and application technology, abundant healthy big data and industrial resources, and accelerate the development of a "patient-centric" digital full life cycle health management system in the medical and healthcare field. In order to fully grasp the characteristics of the healthcare industry and the development trends of the data-driven economy, the Group will focus on the layout of three business segments, namely To B, To C and To R.

3) 生態化的產業平台。我們已經搭建了處於領先地位的健康行業會議／會展活動和媒介服務組合，為行業參與者構建價值生態鏈。該平台也是本集團面向產業客戶的關鍵產品營銷場景，幫助本集團與客戶開展深度商業洽談，提高營銷效率和降低銷售成本。本集團主辦的西普會已成功舉辦十七屆，發展成為中國健康產業規格領先、規模領先、影響力領先的前瞻性產業會議，為產業提供前瞻性、系統性的思想與信息交流，從策略到戰略的多元資源對接與合作交互。此外，我們的生態化產平台已觸達醫藥零售專家、藥械廠商專家、藥師、醫師、醫學專家、行業投資者等領域的專業人士合計近百萬。

### 未來展望

根據《數字中國發展報告(2023年)》，2023年數字經濟核心產業增加值估計超過人民幣12萬億元，佔GDP比重10%左右，以雲計算、大數據等為代表的新興業務收入逐年攀升，雲計算、大數據業務收入較上年增長37.5%。近年來，以大數據、雲計算、人工智能等為代表的新一輪信息技術迅猛發展，推動我國數字經濟蓬勃發展。在中國積極推動「數據要素X」三年行動計劃的背景下，本集團將充分利用數據治理與應用技術、豐富的健康大數據、產業資源等自身核心優勢，加快在醫療健康領域打造「以患者為中心」的數字化全生命週期健康管理體系。為充分把握健康產業特點以及數據要素經濟發展趨勢，本集團將聚焦To B、To C和To R三個業務板塊的佈局。

## MANAGEMENT DISCUSSION AND ANALYSIS 17

### 管理層討論及分析

#### TO B BUSINESS

The Group has had a clear lead in the To B business. In order to further expand the To B business, we will further promote the iterative innovation of products and services, open up “in-hospital + out-of-hospital” medical and pharmaceutical data, and help customers speed up the digital construction through high-quality SaaS products and professional services, build up the ability to make quick decisions, connect targeted markets and efficiently operate, in order to fully respond to industry competition and seize market opportunities.

In order to better serve medical product suppliers, the Group will: 1) continue to introduce more B2C data, O2O data and internal data to improve the type and scale of data, build a diversified and stable all-channel healthcare industry data base, ensure data quality, and improve data timeliness; 2) develop potential models and prediction models, fully tap the value of data, build a pharmaceutical all-channel research system including databases, knowledge bases, business models, data models, and policy information bases, and support the development of more products and services; 3) with “medicines, buyers, and pharmacies/hospitals” as three core, provide customers with in-depth insight and consultation through services such as medicine market insight, consumer research insight and terminal precision strategy research, and expand the market of leading customers; 4) create a standard product system of data visualisation SaaS tools to meet the common data monitoring requirements of customers in the process of marketing management and decision-making, help customers gain timely and rapid insight into market data trend changes, and improve decision-making efficiency. Through this action, the Group will achieve rapid customer expansion in the long-tail market and achieve rapid growth in the revenue scale of SaaS products; and 5) provide flow data governance tools and services, provide digital scenario design and implementation planning services through decision analysis models and combination of internal and external data resources, help customers improve internal human efficiency, promote change management and accurately explore growth opportunities.

#### To B 業務

本集團在To B業務已經構建了明顯的領先優勢，為進一步拓展To B業務規模，我們將進一步推動產品和服務的迭代創新，打通「院內+院外」醫療醫藥數據，通過高質量的SaaS產品和專業服務，助力客戶加快數字化建設，建立快速決策能力、精準市場連接能力和高效運營能力，充分應對行業競爭，搶佔市場先機。

為了更好地服務醫療產品供應商，本集團將：  
1)繼續引入更多B2C數據、O2O數據和院內數據以提升數據種類和規模，並構建多樣化、穩定性強的全渠道健康產業數據基座，保障數據質量，提升數據時效。2)開發潛力模型和預測模型，充分挖掘數據價值，建設包括數據庫、知識庫、商業模型、數據模型、政策信息庫在內的醫藥全渠道研究體系，支持開發更多產品和服務。3)以「藥品、購藥者、藥店/醫院」三大要素為核心，通過藥品市場洞察、消費者研究洞察和終端精準策略研究等服務為客戶提供深度洞察諮詢，擴大頭部客戶市場。4)打造數據可視化SaaS工具的標準產品體系，滿足客戶在市場營銷管理和決策過程中的常規數據監測需求，助力客戶及時快速洞察市場數據趨勢變化，提高決策效率。本集團將通過本項舉措在長尾市場實現快速拓客，實現SaaS產品營收規模的快速增長。5)提供流向數據治理工具和服務，通過決策分析模型以及結合內外部數據資源，提供數字化場景設計與落地規劃服務，助力客戶提升內部人效，推動變革管理和精準挖掘增長機會。

## 18 MANAGEMENT DISCUSSION AND ANALYSIS

### 管理層討論及分析

Medical retail enterprises are now facing many changes and challenges such as digital transformation, service transformation and new business channel expansion. The Group will be committed to building a system + service + content integrated solution through SIC, and through in-depth industry understanding and the application of digitalisation, AI and other sci-tech capabilities, assist medical retail enterprises to better manage store staff, improve expertise and execution, improve per capita sales output, better operate members, improve member activity and repurchase sales rate, and precipitate the behaviour data of store staff and members, build an accurate portrait to help medical retail enterprises achieve more accurate decision-making, enhance customer trust and achieve a win-win situation with customers through professional services, and promote SIC to connect more medical retail enterprises so as to gain more market share. Through SIC complete digital foundation and service capabilities in the chain field, the Group will further build a digital platform connecting medical retailers and medical product suppliers, help medical product suppliers improve the marketing efficiency of the retail field, integrate more medical and health services, bring more resources and business opportunities to chain drugstores, and provide more effective medical and health solutions for individual customers.

Based on the above initiatives, we expect that customer demand for digitization can be satisfied to the largest extent, and a unified data application standard can be reached by the Group and healthcare industry players during their sustainable data business cooperation, which will promote the establishment of industry standards and advance the industry digital transformation and upgrading.

醫藥零售企業正面臨數字化轉型，服務轉型和新賽道拓展等諸多變化和挑戰。本集團將通過SIC致力於構建系統+服務+解決方案，通過對行業的深入理解，以及對數字化、人工智能等科技能力的應用，協助醫療零售企業更好地管理店員，提升專業能力和執行力，提升人均銷售產出，更好地運營會員，提升會員活躍度和複購銷售率，沉澱店員與會員的行為數據，搭建精準畫像，助力醫藥零售企業實現更精準的決策，通過專業服務，提升客戶信任，與客戶實現共贏，同時推動SIC連接更多醫藥零售企業，獲得更大的市場份額。通過SIC在連鎖領域完整的數字化底座及服務能力，進一步打造連接醫藥零售企業與醫療產品供應商的數字化平台，幫助醫療產品供應商提升零售場域營銷效能的同時，融入更多醫藥健康服務，為連鎖藥店帶來更多資源及商業機會，從而為個人客戶提供更有效的醫藥健康解決方案。

我們希望通過實施以上行動，最大限度滿足客戶的數字化需求，在持續的數據業務合作中促進本集團與健康產業參與者統一數據應用標準，加快建立行業標準，推動行業數字化轉型升級。

## TO C BUSINESS

On the basis of the To B business development, the Group is accelerating the deployment of customer-end (To C) health service business based on its deep insight into the medical and healthcare industry chain, resource integration and the increasing medical and healthcare needs of C-end customers. Based on individual resident's personal requirements and health conditions, the Group will build differentiated service capabilities and competitive advantages through big data, AI and cloud computing, provide the individual health service platform including health management and digital full course precision service, realise efficient health management and high-quality diagnosis and treatment management, and increase individual health level and diagnosis/treatment quality.

According to the public available statistics, the number of physical examinations in China has exceeded 500 million per year, and with the improvement of national health awareness, the number of physical examinations and the demand for health management will continue to grow, and the number of physical examinations in China will reach 870 million per year.

As one of the important starting points for the Group to expand the To C business, the AI-MDT system will continue to innovate and expand functions, and provide physical examination institutions and hospitals with digital overall solutions including intelligent general examination, health management services, health follow-up SCRM and digital healthcare, help physical examination centers improve the efficiency of general examination and member management, create a digital full life cycle health management service system for individual users, and finally provide individual users with a variety of services such as AI-MDT in-depth physical examination report services, health follow-up services for sub-healthy populations, single-disease health management services and personalised physical examination services, so as to meet the diversified post-examination health management needs of individual users. The Group will continue to rapidly expand the To C business through the two main channels including physical examination institutions and hospitals, so that a wider range of people can access AI-MDT and the corresponding health management services, thereby improving the individual health.

## To C 業務

本集團在發展 To B 業務的基礎上，基於對醫療健康產業鏈的深刻洞察、資源整合，結合 C 端客戶逐步提升的醫療健康需求，正加快佈局個人端 (To C) 健康服務業務。根據個人居民的個性化需求和健康情況，通過大數據、人工智能和雲計算構建差異化服務能力和競爭優勢，提供包含健康管理和數字化全病程精準服務的個人健康服務平台，實現高效健康管理和高質量診療管理，提升個人健康水平及診療質量。

根據公開數據，我國體檢人群已經突破 5 億人次/年，而伴隨國民健康意識提高，體檢人數和健康管理需求將保持增長，我國體檢人群可達到 8.7 億人次/年。

作為本集團拓展 To C 業務的重要抓手之一，卓睦烏 AI-MDT 系統將持續創新拓展功能，為體檢機構和醫院提供包含智能總檢、健康管理服務、健康隨訪 SCRM、數字醫療功能為一體的智能整體解決方案，幫助體檢中心提升總檢效率和會員管理效率，打造個人用戶的數字化全生命週期健康管理服務體系，最終為個人用戶提供 AI-MDT 深度體檢報告服務、亞健康人群健康隨訪服務、單病種健康管理服務和個性化體檢服務等多種服務，以滿足個人用戶的多樣化體檢後健康管理需求。本集團將在體檢機構和醫院兩個主要渠道快速拓展 To C 業務，讓更廣闊人群觸及 AI-MDT 以及相應健康管理服務，提升個人健康水平。

## 20 MANAGEMENT DISCUSSION AND ANALYSIS

### 管理層討論及分析

At the same time, the Group will also build a digital platform for the whole course management service for individual patients, help seriously ill patients precisely match with multi-disciplinary expert team, formulate high-quality comprehensive diagnosis and treatment plans, connect with the most suitable medical resources, carry out the whole course management for patients, and comprehensively improve the treatment effect.

#### TO R BUSINESS

We will give full play to the accumulated leading edge of the To B business, and based on our deep insight into the customer market and marketing field of B-end enterprises, we will gradually explore innovative products, establish our presence in R&D field, focus on creating digital empowerment platform for biomedical R&D (To R), work with major players such as medical institutions, innovative drug enterprises, CRO companies, CMO companies, pharmaceutical retail enterprises to establish an industrial cooperation ecology, provide integrated solutions for in-hospital preparations translation, innovative drug and medical devices R&D, foreign products introduction through digital innovation services, and drive the investment, introduction, R&D and promotion of medicine innovation. Currently, we have entered into relevant cooperation agreements with several partners. For example, in April 2024, we formally signed a strategic cooperation agreement with Lecheng Pilot Zone, pursuant to which the parties would jointly promote the construction of an ecological platform for the medical and healthcare industry, the transformation of innovative drugs and real-world study, and promote the high-quality development of the healthcare industry.

同時，本集團還將為個人患者搭建全病程管理服務的數字化平台，幫助重病患者精準匹配多學科醫生專家團隊，制定高質量綜合診療方案，連接最佳適配的醫療資源，對患者開展全病程管理，全面提高治療效果。

#### To R 業務

我們充分發揮To B業務積累的領先優勢，基於對B端企業客戶市場及營銷領域的深刻洞察，逐步開拓創新產品、佈局研發領域，致力於打造生物醫藥研發(To R)的數字化賦能平台，聯合醫療機構、創新藥企業、CRO公司、CMO公司、醫藥零售企業等主體建立產業合作生態，通過數字化創新服務，為院內製劑轉化、創新藥械研發、海外產品引進提供整體解決方案，推動藥物創新的投資、引進、研發和推廣。目前，我們已經和多個合作方簽訂相關合作協議，例如，2024年4月我們和樂城先行區正式簽約達成戰略合作，雙方將共同推進醫療健康產業的生態平台建設、創新藥轉化與真實世界研究，推動健康產業高質量發展。

In next stage, we will continue to expand our business layout, enhance our data scale and explore more commercial models. We will integrate existing resources and help innovative pharmaceutical and medical device companies to effectively connect patients, doctors and experts in the aspects of program design, intelligent systems and operational services. Based on the network of hospitals and experts accumulated in the big data platform and the patient management services, and focusing on the full life-cycle of pharmaceutical and medical devices from clinical development to post-launch marketing, we provide enterprises with scientific research collaboration, artificial intelligence and medical inter-disciplinary research and collaborative innovation, and AI technology-based clinical data processing, thereby rapidly achieving the best commercialisation solutions.

In the long-term development of healthcare industry and digital element industry, the Group will continue to explore and practise in the field of healthcare industry services, improve product quality and professional service capabilities, to 1) provide digital applications and solutions for enterprises; 2) provide personalised high quality health services for individual users; and 3) provide digital empowerment for the innovations in life science field, build industry benchmark and leading capabilities, stimulate new quality productivity and actively drive the high-quality development of the medical and healthcare industry.

接下來，我們將持續擴大業務佈局、提升數據規模以及探索更多商業化模式。我們將整合現有資源，幫助創新藥械企業在方案設計、智能系統、運營服務三個方面，有效聯結患者、醫生、專家，基於大數據平台和患者管理服務積累的醫院和專家網絡，圍繞藥物和醫療器械從臨床開發到上市後營銷的全生命週期，為企業提供包括科研協作、人工智能+醫學交叉研究協同創新、基於AI技術的臨床數據處理，迅速找到商業化最佳實踐方案。

在健康產業和數字要素產業保持長期發展的趨勢下，本集團將不斷在健康產業服務領域探索和實踐，提升產品質量和專業服務能力，1)為企業提供數字化應用和解決方案；2)為個人用戶提供個性化的高質量健康服務；3)為生命科學領域創新提供數字化賦能，打造行業標杆和引領能力，激發新質生產力，積極推動健康醫療行業實現高質量發展。

## 22 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

### FINANCIAL REVIEW

#### Revenue

The Group's revenue increased by approximately 10.1% from approximately RMB145.0 million as of 30 June 2023 to RMB159.5 million as of 30 June 2024, which was mainly due to the increase in revenue from the Smart Retail Cloud and the business of SaaS products.

#### Cost of Sales

The Group's cost of sales primarily consisted of (i) costs related to the daily operation and maintenance of our solutions and products and our employee benefits; (ii) costs associated with our marketing campaigns and provision of services to our clients; and (iii) event costs mainly relating to venue and equipment rentals, event planning and organisation services fees, accommodation and catering costs. The Group's cost of sales increased by approximately 1.4% from approximately RMB69.8 million as of 30 June 2023 to approximately RMB70.7 million as of 30 June 2024, which was mainly due to the increase in cost of sales driven by the increase in revenue from the Group's main business.

#### Gross Profit and Gross Profit Margin

The Group's gross profit increased by approximately 18.1% from approximately RMB75.2 million as of 30 June 2023 to approximately RMB88.8 million as of 30 June 2024. The Group's gross profit margin increased from approximately 51.9% as of 30 June 2023 to approximately 55.7% as of 30 June 2024.

#### Other Income and Gains

Other income and gains primarily consisted of (i) bank interest income; (ii) government grants; and (iii) foreign exchange gains. The Group recorded other income and gains of approximately RMB23.5 million as of 30 June 2024, representing a decrease of approximately 34.5% as compared to approximately RMB35.8 million as of 30 June 2023, which was mainly due to the decrease in foreign exchange gains.

#### 財務回顧

##### 收入

本集團的收入由截至2023年6月30日止約人民幣145.0百萬元增加約10.1%至截至2024年6月30日止人民幣159.5百萬元。收入增長主要來自於智慧零售雲和SaaS產品業務收入的增加。

##### 銷售成本

本集團的銷售成本主要包括(i)與我們的解決方案及產品相關的日常運營及維護與員工福利成本；(ii)主要與我們的營銷活動以及為客戶提供服務相關的成本；及(iii)主要與租用場地及設備、活動策劃與組織服務費、住宿與餐飲成本有關的活動成本。本集團的銷售成本由截至2023年6月30日止約人民幣69.8百萬元增加約1.4%至截至2024年6月30日止約人民幣70.7百萬元，主要是由於本集團主營業務收入提升，致使銷售成本增加。

##### 毛利及毛利率

本集團的毛利由截至2023年6月30日止約人民幣75.2百萬元增加約18.1%至截至2024年6月30日止約人民幣88.8百萬元。毛利率由截至2023年6月30日止約51.9%上升至截至2024年6月30日止約55.7%。

##### 其他收入及收益

其他收入及收益主要包括(i)銀行利息收入；(ii)政府補助；及(iii)匯兌收益。本集團截至2024年6月30日錄得其他收入及收益約人民幣23.5百萬元，較截至2023年6月30日止約人民幣35.8百萬元減少約34.5%，主要是由於匯兌收益減少。

## MANAGEMENT DISCUSSION AND ANALYSIS 23

### 管理層討論及分析

#### Selling and Distribution Expenses

Selling and distribution expenses mainly consisted of (i) employee benefit expenses for employees responsible for sales and marketing functions; (ii) travel and transportation expenses related to offline marketing campaigns, the development and maintenance of customer relationship and production of advertising materials; and (iii) general office expenses. As of 30 June 2024, the Group's selling and distribution expenses amounted to approximately RMB17.2 million, representing an increase of approximately 13.7% as compared to approximately RMB15.1 million as of 30 June 2023, which was mainly due to the increase in the number of employees and their benefits expenses.

#### Administrative Expenses

The Group's administrative expenses primarily consisted of (i) employee benefits expenses; and (ii) professional fees. The Group's administrative expenses increased by approximately 12.2% from approximately RMB15.1 million as of 30 June 2023 to approximately RMB17.0 million as of 30 June 2024, which was mainly attributable to the Company's employee benefits expenses for the first half of 2024.

#### Research and Development Costs

The Group's research and development costs primarily consisted of (i) employee benefits expenses; (ii) depreciation of right-of-use assets; and (iii) technology services fees and general office expenses. The Group's research and development costs increased by approximately 6.1% from approximately RMB27.2 million as of 30 June 2023 to approximately RMB28.9 million as of 30 June 2024, primarily due to the increase in employee benefits expenses.

#### Profit before Tax

The Group's profit before tax decreased by approximately 11.2% from approximately RMB47.9 million as of 30 June 2023 to approximately RMB42.5 million as of 30 June 2024, mainly due to the decrease in the Group's foreign exchange gains.

#### 銷售及分銷開支

銷售及分銷開支主要包括(i)負責銷售和營銷職能的員工的福利開支；(ii)與線下營銷活動與客戶關係發展及維護、廣告素材製作相關的差旅及交通開支；及(iii)一般辦公開支。銷售及分銷開支由截至2023年6月30日止約人民幣15.1百萬元增加約13.7%至截至2024年6月30日止約人民幣17.2百萬元，主要由於我們員工人數及福利開支的增加所致。

#### 行政開支

本集團的行政開支主要包括(i)員工福利開支；及(ii)專業費用。本集團的行政開支由截至2023年6月30日止約人民幣15.1百萬元增加約12.2%至截至2024年6月30日止約人民幣17.0百萬元，增加的費用主要為2024上半年本公司的員工福利開支。

#### 研究及開發成本

本集團的研究及開發成本主要包括(i)員工福利開支；(ii)使用權資產折舊；及(iii)技術服務費用與一般辦公室開支。本集團的研究及開發成本由截至2023年6月30日止約人民幣27.2百萬元增加約6.1%至截至2024年6月30日止約人民幣28.9百萬元，主要由於員工福利開支增加所致。

#### 除稅前溢利

本集團的除稅前溢利由截至2023年6月30日止約人民幣47.9百萬元減少約11.2%至截至2024年6月30日止約人民幣42.5百萬元，主要是由於本集團匯兌收益降低導致。



## 24 MANAGEMENT DISCUSSION AND ANALYSIS

### 管理層討論及分析

#### Income Tax Expense

The Group's income tax expense decreased by approximately 78.7% from approximately RMB0.9 million as of 30 June 2023 to approximately RMB0.2 million as of 30 June 2024, mainly because the subsidiaries offset tax losses generating from prior years during the period.

#### Profit for the Period

As a result of the foregoing, the Group's profit for the period decreased by approximately 9.8% from approximately RMB47.0 million as of 30 June 2023 to approximately RMB42.3 million as of 30 June 2024. The operating profit recorded a year-on-year increase of approximately 62.1%. The Group's net profit (excluding foreign exchange gain or loss) increased by approximately 23.2% from approximately RMB32.5 million as of 30 June 2023 to approximately RMB40.1 million as of 30 June 2024, and the net profit margin (excluding foreign exchange gain or loss) increased by 2.7 percentage points year-on-year from 22.4% as of 30 June 2023 to 25.1% as of 30 June 2024.

#### 所得稅開支

本集團的所得稅開支由截至2023年6月30日止約人民幣0.9百萬元減少約78.7%至截至2024年6月30日止約人民幣0.2百萬元，主要由於本期子公司彌補過往年度稅項虧損所致。

#### 期內溢利

由於以上所述，本集團期內溢利由截至2023年6月30日止約人民幣47.0百萬元減少約9.8%至截至2024年6月30日止約人民幣42.3百萬元。經營利潤同比增長約62.1%。本集團的不含匯兌損益的淨利潤由截至2023年6月30日止約人民幣32.5百萬元增加約23.2%至截至2024年6月30日止約人民幣40.1百萬元，淨利潤率(不含匯兌損益)由截至2023年6月30日止的22.4%上升至截至2024年6月30日止的25.1%，同比增長2.7個百分點。

		<b>As of 30 June 2024 截至2024年 6月30日 RMB'000 人民幣千元</b>	As of 30 June 2023 截至2023年 6月30日 RMB'000 人民幣千元
Operating profit	經營利潤	<b>20,035</b>	12,362
Net profit (excluding foreign exchange gain or loss)	淨利潤(不包含匯兌損益)	<b>40,057</b>	32,525
Net profit margin (excluding foreign exchange gain or loss)	淨利潤率(不包含匯兌損益)	<b>25.1%</b>	22.4%

## MANAGEMENT DISCUSSION AND ANALYSIS 25

### 管理層討論及分析

#### Liquidity and Capital Resources

As of 30 June 2024, the Group financed its operations mainly through cash generated from the Group's operating activities and the net proceeds from the Global Offering. The Group intends to continuously finance its expansion and business operations using a combination of cash generated from operating activities and the net proceeds from the Global Offering.

#### Cash and Cash Equivalents

The Group maintains a strong cash position. As of 30 June 2024, the Group's total cash and cash equivalents amounted to approximately RMB23.8 million. The Group further invests in domestic and overseas time deposits and financial assets at fair value through profit or loss.

#### Borrowings

As of 30 June 2024, the Group did not have any short-term or long-term bank borrowings and had no outstanding bank and other borrowings and other indebtedness apart from lease liabilities for the relevant lease terms amounting to approximately RMB13.9 million in aggregate.

#### Gearing Ratio

The gearing ratio, which is calculated by dividing total liabilities by total equity, was 19.1% as at 30 June 2024 (31 December 2023: approximately 13.9%).

#### Foreign Currency Risk

The Group has transactional currency exposures and are subject to foreign currency risk arising from fluctuations in exchange rates between RMB and US\$. As at 30 June 2024, the Group had transactional currency exposures. Such exposures arose from its cash and cash equivalents in US\$. The Group is currently not engaged in hedging activities that are designed or intended to manage foreign exchange rate risk. The Group will continue to monitor foreign exchange activities and make its best efforts to protect the cash value of the Group.

#### 流動資金及資本資源

截至2024年6月30日止，本集團主要通過本集團經營活動所得現金及全球發售所得款項淨額籌集營運資金。本集團擬繼續利用經營活動所得現金和全球發售所得款項淨額為擴張及業務運營提供資金。

#### 現金及現金等價物

本集團維持強勁現金狀況。截至2024年6月30日止，本集團的現金及現金等價物總值約人民幣23.8百萬元，集團將更多資金投資於境內外定期存款以及按公平值計入損益的金融資產。

#### 借款

截至2024年6月30日止，本集團並無任何短期或長期銀行借款，除總計約人民幣13.9百萬元的相關租賃條款的租賃負債外，亦無未償還銀行及其他借款及其他債務。

#### 資產負債比率

截至2024年6月30日，資產負債比率(按總負債除以權益總額計算)為19.1%(2023年12月31日：約13.9%)。

#### 外匯風險

本集團面臨交易貨幣風險，並面臨著因人民幣與美元之間的匯率波動而產生的外幣風險。截至2024年6月30日，本集團存在交易貨幣風險。有關風險來自以美元計值的現金及現金等價物。本集團現時未有從事旨在或意在管理外匯匯率風險的對沖活動。本集團將繼續監察外匯活動，並盡最大努力保障本集團的現金價值。

## 26 MANAGEMENT DISCUSSION AND ANALYSIS

### 管理層討論及分析

#### Charge on Assets

As at 30 June 2024, the Group did not pledge any of its assets.

#### Cash Flow and Capital Expenditure

As at 30 June 2024, the Group's capital expenditures mainly incurred for the acquisition of equipment and software and leasehold improvements was approximately RMB0.5 million, representing a decrease of approximately 71.6% as compared to as of 30 June 2023. The Group intends to fund future capital expenditures from the existing cash balance, cash generated from operating activities and proceeds from the Global Offering. The Group will continue to incur capital expenditures to meet the expected business growth, and may reallocate funds for capital expenditures and long-term investments based on the Group's ongoing business needs.

#### Contingent Liabilities and Guarantees

As at 30 June 2024, the Group did not have any significant contingent liabilities, guarantees or any material litigation against the Group.

#### Significant Acquisitions or Disposals and Future Plans for Significant Investments

The Group did not have any significant acquisitions or disposals of subsidiaries, associates and joint ventures as at 30 June 2024.

As at 30 June 2024, none of each individual investment held by the Group constituted 5% or more of the total assets of the Group, and there is no future plan for any material investment or capital assets.

#### Employees and Staff Costs

As at 30 June 2024, the Group had a total of 778 (30 June 2023: 698) full time employees. During the Reporting Period, the Group recognised staff costs of approximately RMB75.4 million, representing an increase of approximately 13.2% as compared to as at 30 June 2023.

#### 資產抵押

截至2024年6月30日，本集團並無抵押任何資產。

#### 現金流量及資本開支

截至2024年6月30日，本集團資本開支主要就設備和軟件收購及租賃物業裝修所產生，約人民幣0.5百萬元，較截至2023年6月30日止下降約71.6%。本集團擬以現有銀行結餘、經營活動所得的現金及全球發售的所得款項支付未來資本開支。本集團將繼續產生資本開支，以滿足業務的預期增長，並可能根據本集團持續的業務需要將資金重新分配以用於資本開支及長期投資。

#### 或然負債及擔保

截至2024年6月30日，本集團並無任何重大的或然負債、擔保或針對本集團的任何重大訴訟。

#### 重大收購或出售及主要投資未來計劃

截至2024年6月30日，本集團並無就附屬公司、聯營企業及合營企業進行任何重大收購或出售事項。

截至2024年6月30日，本集團持有的每項投資均不構成本集團總資產的5%或以上，且未來亦無重大投資或資本資產計劃。

#### 員工及員工成本

於2024年6月30日，本集團共有778名全職員工(2023年6月30日：698名)。報告期內，本集團確認員工成本約人民幣75.4百萬元，較2023年6月30日上升約13.2%。

# MANAGEMENT DISCUSSION AND ANALYSIS

## 管理層討論及分析

The following table sets forth the number of employees by function as at 30 June 2024.

下表載列於2024年6月30日按職能劃分的員工人數：

Function	職能	Number	Percentage to the total number of employees 佔總人數的比例
Solutions and Products	解決方案及產品	346	44%
Research and Development	研發	214	28%
Sales and Marketing	銷售與營銷	143	18%
General and Administrative	總務與行政	75	10%
Total	合計	778	100%

Employees are the valuable assets and the foundation for sustainable development of the Group. The Group highly appreciates the career development of its employees, and we have developed a comprehensive vocational training system and a sound remuneration and promotion system to continuously train, attract and retain talents.

員工是本集團的寶貴資產，也是本集團可持續發展的基礎。本集團高度重視員工的職業發展，我們制定了全面的職業培訓體系和完善的薪酬與晉升體系，以不斷培養、吸引及留聘人才。

Leveraging on our influence and expertise in the industry, we are able to continue to attract outstanding versatile talents. As at 30 June 2024, approximately 39% of our employees with medical and pharmaceutical expertise and experience and approximately 17% with artificial intelligence and computer science expertise and experience.

憑藉我們在行業內的影響力和專業性，我們能夠持續吸引優秀的複合型人才。於2024年6月30日，約有39%的員工擁有醫學和醫藥的背景和經驗，約有17%的員工擁有人工智能和計算機科學的背景和經驗。

In addition, the Company has adopted the Share Option Scheme and the Share Award Scheme to motivate talented employees and attract talented persons for the further development of the Group.

此外，本公司已採納購股權計劃及股份激勵計劃，以激勵優秀員工並吸引優秀人才，以促進本集團進一步發展。

### Subsequent Events

No significant events that require additional disclosure or adjustments occurred after the end of the Reporting Period and up to the date of this report.

### 期後事項

本集團自報告期結束後至本報告日期並無發生須進一步披露或調整的重大事項。

## 28 CORPORATE GOVERNANCE AND OTHER INFORMATION 企業管治及其他資料

### CORPORATE GOVERNANCE CODE

The Company is committed to maintaining good corporate governance standards and believes that they are essential for the Company to safeguard shareholders' interests and enhance corporate value. The Company has adopted the principles and provisions of the CG Code as set out in Part 2 of Appendix C1 to the Listing Rules. To the best knowledge of the Directors, save and except for code provision C.2.1 of CG Code as set out below, the Company has complied with all the applicable code provisions set out in the CG Code during the Reporting Period.

Pursuant to code provision C.2.1 of the CG Code, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. The Company does not have a separate chairman and chief executive officer and Mr. Wu Yushu currently performs these two roles concurrently. Mr. Wu is responsible for the overall strategic planning and overall management and daily operations of the Group. Mr. Wu has over 20 years of experience in the healthcare information and data analysis industries and has been instrumental to the growth and business expansion of the Company since the Group was founded in 2007. The Board believes that vesting the roles of Chairman and Chief Executive Officer in the same person ensures consistency in the management and strategic layout of the Group. The Board and the senior management are composed of experienced individuals who ensure a balance of power and authority in their operations and the current structure will enable the Company to make and implement decisions more promptly and effectively.

The Company will review its corporate governance practices from time to time and strive to enhance its alignment with business operations and developments to ensure compliance with statutory and latest business developments.

### 企業管治常規

本公司致力於維持良好的企業管治標準，並堅信其對本公司保障股東利益、提升企業價值至關重要。本公司已採納上市規則附錄C1第2部分所載企業管治守則的原則及條文。據董事所深知，除下文所載企業管治守則條文第C.2.1條外，本公司已於報告期內遵守企業管治守則所載所有適用守則條文。

根據企業管治守則條文第C.2.1條規定，董事長及首席執行官的職務應有區分，不應由同一人擔任。本公司並無區分董事長及首席執行官，由吳鬱抒先生同時兼任。吳先生負責本集團的整體戰略規劃及全面管理及日常營運，吳先生於醫療健康信息及數據分析行業擁有逾20年經驗，自2007年創立本集團以來，對本公司的增長及業務擴充至關重要。董事會相信，由同一人兼任董事長與首席執行官的角色，可確保本集團的管理及戰略佈局貫徹一致。董事會及高級管理層由經驗豐富的人才組成，在營運過程中會確保權力及權限的平衡，現行架構將使本公司能夠更迅速及有效地作出及實施決策。

本公司將不時檢討企業管治常規，並致力於加強業務運作及發展相適應，以確保其符合法定及業務最新發展。

## COMPLIANCE WITH MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS OF LISTED ISSUERS

The Company has adopted the Model Code as set out in Appendix C3 to the Listing Rules as its own code of conduct regarding Directors' securities transactions.

The Company's relevant employees, who because of his/her office or employment, are likely to be in possession of inside information of the Company, are also subject to the Model Code. Having made specific enquiries of all the Directors and the relevant employees, they have confirmed that they have complied with the Model Code during the Reporting Period.

## CHANGES IN INFORMATION OF DIRECTORS AND CHIEF EXECUTIVES

The changes in information of Directors and chief executives during the Reporting Period are set out below:

Ms. Wang Danzhou was appointed as the independent Director of Guangdong Tecsun Science & Technology Co., Ltd. (廣東德生科技股份有限公司) (stock code: 002908) on 24 May 2024 and Shenzhen Hobbywing Co., Ltd. (深圳市好盈科技股份有限公司) on 14 June 2024, respectively.

Mr. Wei Bin has resigned from his position as the independent non-executive Director of Honghua Group Limited (stock code: 196) on 28 June 2024.

Save as disclosed above, since the date of the 2023 annual report of the Company and up to the date of this interim report, there has been no change to the biographical details of Directors and the senior management which is required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

## 遵守上市發行人董事進行證券交易的標準守則

本公司已採納上市規則附錄C3所載的標準守則，作為其本身有關董事進行證券交易的行為守則。

本公司的相關僱員因職務或受僱情況而可能擁有本公司的內幕消息，亦須受標準守則規限。經向全體董事及相關僱員作出具體查詢後，彼等已確認彼等於報告期間一直遵守標準守則。

## 董事及最高行政人員資料變更

報告期內，董事及最高行政人員的資料變動如下：

王丹舟女士於2024年5月24日獲委任為廣東德生科技股份有限公司(股份代碼：002908)的獨立董事及於2024年6月14日獲委任為深圳市好盈科技股份有限公司的獨立董事。

魏斌先生於2024年6月28日辭任宏華集團有限公司(股份代碼：196)的獨立非執行董事。

除上文所披露者外，自本公司2023年年報日期起至本中期報告日期止，根據上市規則第13.51B(1)條必須披露的董事及高級管理人員資料並無發生任何變動。

## 30 CORPORATE GOVERNANCE AND OTHER INFORMATION 企業管治及其他資料

### DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 30 June 2024, the interests and short positions of the Directors and chief executive of the Company in the Shares, underlying Shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO), which were required to be (i) notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they are taken or deemed to have under such provisions of the SFO), or (ii) entered in the register kept by the Company pursuant to section 352 of the SFO, or (iii) notified to the Company and the Stock Exchange under the Model Code, were as follows:

### 董事及最高行政人員於股份、相關股份及債權證中的權益及淡倉

於2024年6月30日，本公司董事及最高行政人員於本公司或其任何相關法團（定義見證券及期貨條例第XV部）的股份、相關股份及債權證中擁有(i)根據證券及期貨條例第XV部第7及8分部須知會本公司及聯交所的權益或淡倉（包括根據證券及期貨條例有關條文被當作或視為擁有的權益及淡倉），或(ii)根據證券及期貨條例第352條須記入本公司存置的登記冊內的權益或淡倉，或(iii)根據標準守則須知會本公司及聯交所的權益或淡倉如下：

#### Long Position in the Shares

#### 股份好倉

Name of Director or chief executive	Capacity/Nature of interest	Number of Shares	Total	Approximate percentage of interest in the Company <sup>1</sup> 佔本公司的權益概約百分比 <sup>1</sup>
董事／最高行政人員姓名	身份／權益性質	股份數目	總計	
Mr. Wu Yushu <sup>2</sup> 吳鬱抒先生 <sup>2</sup>	Interest of controlled corporation 受控法團權益	248,737,500		
	Interest of spouse 配偶權益	20,250,000		
			268,987,500	59.54%
Ms. Wang Lifang <sup>2</sup> 王莉芳女士 <sup>2</sup>	Interest of controlled corporation 受控法團權益	87,750,000		
	Interest of spouse 配偶權益	181,237,500		
			268,987,500	59.54%

## CORPORATE GOVERNANCE AND OTHER INFORMATION 31

### 企業管治及其他資料

## Notes:

1. The calculation is based on the total number of 451,770,000 Shares in issue as of 30 June 2024.
2. Mr. Wu and Ms. Wang are the spouse of each other, and are deemed to be interested in the Shares beneficially owned by each other. Mr. Wu wholly owns Wellmark Link Limited and is deemed to be interested in the Shares held by Wellmark Link Limited. Ms. Wang wholly owns WLF Investment Holdings Limited and is deemed to be interested in the Shares held by WLF Investment Holdings Limited. Wellmark Link Limited is the general partner of Rikan Industry Investment Limited Partnership and Ms. Wang, through WLF Investment Holdings Limited, holds approximately 62.8866% interests in Rikan Industry Investment Limited Partnership. They are deemed to be interested in the Shares held by Rikan Industry Investment Limited Partnership.

Save as disclosed above, so far as the Directors are aware, as of 30 June 2024, none of the Directors or chief executive of the Company had any interest or short positions in the Shares, underlying Shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which were required to be (i) notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they are taken or deemed to have under such provisions of the SFO), or (ii) entered in the register kept by the Company pursuant to section 352 of the SFO, or (iii) notified to the Company and the Stock Exchange under the Model Code.

## 附註：

1. 截至2024年6月30日已發行股份總數451,770,000股計算。
2. 吳先生及王女士彼此為配偶，故被視為於彼此各自實益擁有的股份中擁有權益。吳先生全資擁有盈連有限公司，故被視為於盈連有限公司持有的股份中擁有權益。王女士全資擁有WLF Investment Holdings Limited，故被視為於WLF Investment Holdings Limited持有的股份中擁有權益。盈連有限公司為Rikan Industry Investment Limited Partnership的普通合夥人，而王女士透過WLF Investment Holdings Limited持有Rikan Industry Investment Limited Partnership約62.8866%權益。彼等被視為於Rikan Industry Investment Limited Partnership持有的股份中擁有權益。

除上文所披露者外，就董事所知，截至2024年6月30日，概無董事或本公司最高行政人員於本公司或其任何相關法團（定義見證券及期貨條例第XV部）的股份、相關股份或債權證中擁有(i)根據證券及期貨條例第XV部第7及8分部須知會本公司及聯交所的權益或淡倉（包括根據證券及期貨條例有關條文被當作或視為擁有的權益及淡倉），或(ii)根據證券及期貨條例第352條須記入本公司存置的登記冊內的權益或淡倉，或(iii)根據標準守則須知會本公司及聯交所的權益或淡倉。



## 32 CORPORATE GOVERNANCE AND OTHER INFORMATION 企業管治及其他資料

### SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at 30 June 2024, the following persons (other than the Directors and chief executive of the Company) had an interest or short position in the Shares and underlying Shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO as recorded in the register required to be kept by the Company, pursuant to section 336 of the SFO:

### 主要股東於股份及相關股份中的權益及淡倉

於2024年6月30日，按本公司根據證券及期貨條例第336條須存置的登記冊所記錄，以下人士(董事及本公司最高行政人員除外)於本公司股份及相關股份中擁有根據證券及期貨條例第XV部第2及第3分部的條文須向本公司披露的權益或淡倉：

#### Long Position in the Shares

#### 股份好倉

Name	Capacity/Nature of interest	Number of Shares	Total	Approximate percentage of interest in the Company <sup>1</sup> 佔本公司的權益概約百分比 <sup>1</sup>
姓名／名稱	身份／權益性質	股份數目	總計	
Wellmark Link Limited <sup>2</sup> 盈連有限公司 <sup>2</sup>	Beneficial owner 實益擁有人	181,237,500	248,737,500	55.06%
	Interest of controlled corporation 受控法團權益	67,500,000		
WLF Investment Holdings Limited <sup>2</sup>	Beneficial owner 實益擁有人	20,250,000	87,750,000	19.42%
	Interest of controlled corporation 受控法團權益	67,500,000		

# CORPORATE GOVERNANCE AND OTHER INFORMATION

## 企業管治及其他資料

Name	Capacity/Nature of interest	Number of Shares	Total	Approximate percentage of interest in the Company <sup>1</sup> 佔本公司的權益概約百分比 <sup>1</sup>
姓名／名稱	身份／權益性質	股份數目	總計	
Rikan Industry Investment Limited Partnership <sup>2</sup>	Beneficial owner 實益擁有人	67,500,000		14.94%
Montesy Capital Holding Ltd <sup>3</sup>	Beneficial owner 實益擁有人	68,512,500		15.17%
Ms. Wu Meirong <sup>3</sup> 吳美容女士 <sup>3</sup>	Interest of spouse 配偶權益	68,512,500		15.17%
Mr. Li Hanxiong <sup>3</sup> 李捍雄先生 <sup>3</sup>	Interest of controlled corporation 受控法團權益	68,512,500		15.17%
Futu Trustee Limited 富途信託有限公司	Trustee 受託人	42,650,000		9.44%
Mr. Yu Rong <sup>4</sup> 俞熔先生 <sup>4</sup>	Interest of controlled corporation 受控法團權益	22,854,250		5.06%
Shanghai Tianyi Assets Management Co., Ltd <sup>4</sup> 上海天億資產管理有限公司 <sup>4</sup>	Interest of controlled corporation 受控法團權益	22,854,250		5.06%

## 34 CORPORATE GOVERNANCE AND OTHER INFORMATION 企業管治及其他資料

## Notes:

1. The calculation is based on the total number of 451,770,000 Shares in issue as of 30 June 2024.
2. Mr. Wu and Ms. Wang are the spouse of each other, and are deemed to be interested in the Shares beneficially owned by each other. Mr. Wu wholly owns Wellmark Link Limited and is deemed to be interested in the Shares held by Wellmark Link Limited. Ms. Wang wholly owns WLF Investment Holdings Limited and is deemed to be interested in the Shares held by WLF Investment Holdings Limited. Wellmark Link Limited is the general partner of Rikan Industry Investment Limited Partnership and Ms. Wang, through WLF Investment Holdings Limited, holds approximately 62.8866% interests in Rikan Industry Investment Limited Partnership. Therefore, they are deemed to be interested in the Shares held by Rikan Industry Investment Limited Partnership.
3. Montesy Capital Holding Ltd is owned by Mr. Li Hanxiong and Ms. Wu Meirong as to 70% and 30%, respectively. Mr. Li Hanxiong and Ms. Wu Meirong are the spouse of each other, and are therefore deemed to be interested in any Shares in which one another is interested. Therefore, both Mr. Li Hanxiong and Ms. Wu Meirong are deemed to be interested in the Shares held by Montesy Capital Holding Ltd.
4. Tianyi (BVI) Limited and Jiequan Zhongwei Tengyun Limited are controlled by Shanghai Tianyi Assets Management Co., Ltd, which is owned as to 70% by Mr. Yu Rong (俞熔). Therefore, Mr. Yu Rong is deemed to be interested in the Shares in which Shanghai Tianyi Assets Management Co., Ltd is deemed to be interested.

Save as disclosed above, to the knowledge of the Directors, as of 30 June 2024, there is no other person (excluding the Directors and chief executives of the Company) has interests or short positions as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO in the Shares and underlying Shares.

## 附註：

1. 截至2024年6月30日已發行股份總數451,770,000股計算。
2. 吳先生及王女士彼此為配偶，故被視為於彼此各自實益擁有的股份中擁有權益。吳先生全資擁有盈連有限公司，故被視為於盈連有限公司持有的股份中擁有權益。王女士全資擁有WLF Investment Holdings Limited，故被視為於WLF Investment Holdings Limited持有的股份中擁有權益。盈連有限公司為Rikan Industry Investment Limited Partnership的普通合夥人，而王女士透過WLF Investment Holdings Limited持有Rikan Industry Investment Limited Partnership約62.8866%權益。因此均被視為於Rikan Industry Investment Limited Partnership持有的股份中擁有權益。
3. Montesy Capital Holding Ltd由李捍雄先生及吳美容女士分別擁有70%及30%。李捍雄先生及吳美容女士為彼此的配偶，因此被視為於彼此擁有權益的任何股份中擁有權益。因此，李捍雄先生及吳美容女士均被視為於Montesy Capital Holding Ltd持有的股份中擁有權益。
4. Tianyi (BVI) Limited及Jiequan Zhongwei Tengyun Limited由上海天億資產管理有限公司控制，而上海天億資產管理有限公司由俞熔先生擁有70%權益。因此，俞熔先生被視為於上海天億資產管理有限公司被視作擁有權益的股份中擁有權益。

除上文所披露者外，據董事所知，截至2024年6月30日，並無任何其他人士(不包括本公司的董事及最高行政人員)在股份或相關股份中擁有根據《證券及期貨條例》第336條規定由本公司備存的登記冊所記錄的權益或淡倉。

## SHARE OPTION SCHEME

The Company adopted the Share Option Scheme (the “**Share Option Scheme**”) by way of a written resolution passed by all the then Shareholders on 27 April 2022, for the purpose of providing incentive or reward to eligible persons for their contribution to, and continuing efforts to promote the interests of, the Group and for such other purposes as the Board may approve from time to time. During the Reporting Period, no options were granted under the Pre-IPO Share Option Scheme.

The Board may, at its absolute discretion, offer eligible persons (being any director or employee (whether full time or part time), consultant or advisor of the Group who in the sole discretion of the Board has contributed to and/or will contribute to the Group) to subscribe for such number of Shares in accordance with the terms of the Share Option Scheme.

Unless approved by the Shareholders, the maximum number of the Shares issuable upon exercise of all options to be granted under the Share Option Scheme, new Scheme and all other schemes of the Company then existing must not in aggregate exceed 10% of the total number of Shares in issue as at the Listing Date i.e. 45,000,000 Shares, accounting for 9.96% of the total number of Shares in issue.

Unless approved by the Shareholders, the total number of option shares granted or to be granted by Eligible Participants shall not exceed 1% in aggregate of the Shares in issue as at the date of such grant.

## 購股權計劃

本公司於2022年4月27日經當時的全體股東通過書面決議案採納購股權計劃(「**購股權計劃**」)，旨在激勵或獎勵為本集團作出貢獻及持續努力提高本集團利益的合資格人士，以及用於董事會可能不時批准的其他用途。於報告期內，概無根據首次公開發售前購股權計劃授予購股權。

董事會可絕對酌情決定向合資格人士(董事會全權酌情認為曾經及／或將會對本集團有貢獻的本集團任何董事或僱員(無論全職或兼職)、顧問或專業顧問)授出購股權，以按購股權計劃條款認購相關數目的股份。

除非經股東批准，否則根據購股權計劃、新計劃及當時存在的本公司所有計劃行使時可予發行的股份數目上限合共不得超過上市日期已發行股份總數的10%，即45,000,000股，佔已發行股份總數的9.96%。

除非獲股東批准，否則合資格參與人士獲授出或將授出的購股權股份總數不得超出於有關授出當日已發行股份總額的1%。

## 36 CORPORATE GOVERNANCE AND OTHER INFORMATION

### 企業管治及其他資料

The subscription price for a Share in respect of any particular option granted under the Share Option Scheme shall be a price solely determined by the Board and notified to all eligible person and shall be at least the highest of the closing price of the Shares as stated in the Stock Exchange's daily quotations sheet on the date of offer to grant option, the average of the closing prices of the Shares as stated in the Stock Exchange's daily quotations sheet for the five business days immediately preceding the date of offer to grant option, and the nominal value of the Share. A consideration of RMB1.00 is payable on acceptance of the offer of an option or options.

Subject to earlier termination by the Company in general meeting, the Share Option Scheme shall be valid and effective for a period of ten years from the date of adoption of the Share Option Scheme by Shareholders by resolution at a general meeting. Therefore, as of 30 June 2024, the remaining term of the Share Option Scheme is approximately 7.5 years.

During the Reporting Period, no options were granted by the Company, nor any options were exercised, canceled or lapsed under the Share Option Scheme, and there were no outstanding options under the Share Option Scheme.

The number of options available for grant under the Share Option Scheme at the beginning and the end of the Reporting Period were 45,000,000 and 45,000,000, respectively.

#### SHARE AWARD SCHEME

The Company adopted the Share Award Scheme on 5 December 2022 for the Purpose of recognising the contributions by certain Eligible Participants to retain them for the continual operation and development of the Group and to attract outstanding talents for further development of the Group.

Eligible participants of the Share Award Scheme include employees of the Company, its subsidiaries or holding companies, fellow subsidiaries and associated companies (the "Eligible Participants").

根據購股權計劃授出的任何特定購股權的股份認購價由董事會全權釐定並知會所有合資格人士，且該價格不得低於授出購股權當日聯交所報價表所列收市價、授出購股權日期前五個營業日在聯交所報價表所列平均收市價及股份面值三者最高價。接納購股權要約或購股權的應付代價為人民幣 1.00 元。

除非本公司於股東大會上提前終止購股權計劃，否則購股權計劃將於股東在股東大會上以決議案接納購股權計劃後十年期間內生效及有效。因此，截至 2024 年 6 月 30 日，購股權計劃的餘下年期約為 7.5 年。

報告期內，本公司概無根據購股權計劃獲授予、行使、注銷或失效，亦無尚未行使的購股權計劃。

報告期初及結束時根據購股權計劃可供授出之購股權數目分別為 45,000,000 份及 45,000,000 份。

#### 股份獎勵計劃

本公司於 2022 年 12 月 5 日採納股份獎勵計劃，股份獎勵計劃旨在表彰若干合資格參與者的貢獻，以挽留彼等助力本集團的持續運營及發展及吸引優秀人才以促進本集團進一步發展。

股份獎勵計劃的合格參與者為本公司、其附屬公司或本公司的控股公司、同系附屬公司及聯營公司的僱員（「合格參與者」）。

## CORPORATE GOVERNANCE AND OTHER INFORMATION 37

### 企業管治及其他資料

The Board shall not make any further grant of award such that the total number of Shares granted under the Share Award Scheme will exceed 10% of the total number of issued Shares as of the adoption date. On the basis that the total number of issued Shares as of the adoption date is 451,770,000 Shares, the aforesaid 10% limit represents a total of 45,177,000 Shares.

The Board or authorized representative, in its sole discretion, selects any Eligible Participant to participate in the Share Award Scheme as a Selected Participant and determines the number of Award Shares to be granted to each Selected Participant and the terms and conditions under which the Award Shares may vest, provided that the maximum number of awards shall not exceed 1% of the issued share capital of the Company in any twelve-month period.

Subject to any early termination as may be determined by the Board, the Share Aware Scheme shall be valid and effective for a term of ten years commencing on the adoption date, after which no further awards will be granted. As of 30 June 2024, the remaining term of the Share Award Scheme is approximately 8.5 years.

On 5 December 2022, the Company appointed Futu Trustee Limited as the Trustee for the Share Award Scheme. Futu Trustee Limited is a trust company registered under section 78(1) of the Trustee Ordinance (Chapter 29 of the Laws of Hong Kong). It is a third party independent of and not connected with the Company and/or any of its connected persons.

As of 30 June 2024, the Trustee, as instructed by the Board, purchased a total of 42,692,000 Shares on the market, representing approximately 9.45% of the total number of Shares of the Company in issue.

As of 30 June 2024, no award was granted by the Company, nor any award was exercised, canceled or lapsed under the Share Award Scheme, and there was no award outstanding under the Share Award Scheme.

董事會進一步授出的任何獎勵不得導致根據股份獎勵計劃授出的股份總數超過截至採納日期已發行股份總數的10%。基於截至採納日期已發行股份總數為451,770,000股股份，上述10%限額相當於合共45,177,000股股份。

董事會或授權代表全權酌情選定任何合資格參與者為選定參與者參與股份獎勵計劃，並釐定向各選定參與者授出的獎勵股份數目、獎勵股份可能獲歸屬前的條款及條件，但獎勵的最高數目，不得超過本公司任何12個月期間內已發行股本的1%。

股份獎勵計劃自採納日期起計有效期為十年，惟可由董事會決定提早終止，其後將不再授出獎勵。截至2024年6月30日，股份獎勵計劃的剩餘年期約為8.5年。

2022年12月5日，本公司就股份獎勵計劃委任富途信託有限公司為受託人。富途信託有限公司為根據香港法例第29章《受託人條例》第78(1)條註冊的信託公司，為獨立第三方，與本公司及／或其任何關連人士並無關連。

截至2024年6月30日，受託人按照董事會的指示在市場上購買合計42,692,000股股份(佔本公司已發行股份總數約9.45%)。

截至2024年6月30日，本公司概無根據股份獎勵計劃授予、行使、注銷或失效任何股份，亦無尚未行使的股份獎勵。

## 38 CORPORATE GOVERNANCE AND OTHER INFORMATION 企業管治及其他資料

### PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities (including sales of treasury shares) as of 30 June 2024. No treasury shares (as defined under the Listing Rules) were held by the Company as of 30 June 2024.

### INTERIM DIVIDEND

The Board resolved not to declare the payment of any interim dividend for the six months ended 30 June 2024 (For the six months ended 30 June 2023: nil).

### AUDIT COMMITTEE

The Company established the Audit Committee with written terms of reference in compliance with the Corporate Governance Code as set out in Appendix C1 to the Listing Rules. As of the date of this report, the Audit Committee comprises three independent non-executive directors of the Company, namely, Ms. Wang Danzhou, Ms. Du Yilin and Mr. Wei Bin. Mr. Wei Bin is the chairman of the Audit Committee.

The Audit Committee has been reviewed the unaudited interim results of the Group for six months ended 30 June 2024 and confirmed that the applicable accounting principles, standards and requirements had been complied with and adequate disclosures had been made.

### 購買、出售或贖回本公司上市證券

截至2024年6月30日，本公司或其任何附屬公司概無購買、出售或贖回本公司任何上市證券(包括銷售庫存股份)。截至2024年6月30日，本公司並無持有庫存股份(定義見上市規則)。

### 中期股息

董事已決議不宣派截至2024年6月30日止六個月的任何中期股息(截至2023年6月30日止六個月：零)。

### 審核委員會

本公司遵照上市規則附錄C1所載企業管治守則成立審核委員會，並制訂其書面職權範圍。於本報告日期，審核委員會包括本公司三名獨立非執行董事，即王丹舟女士、杜依琳女士及魏斌先生。魏斌先生為審核委員會主席。

審核委員會已審閱本集團截至2024年6月30日止六個月的未經審核中期業績，並確認已遵守適用的會計原則、準則及規定並已作出充分披露。

**USE OF PROCEEDS FROM THE GLOBAL OFFERING**

The Shares of the Company have been listed on the Main Board of the Stock Exchange since 12 July 2022. The Group received net proceeds (including the partial exercise of the over-allotment option and after deduction of underwriting commissions and related costs and expenses) from the Global Offering of approximately HK\$339.6 million (the “**Net Proceeds**”). The Group will continue to utilise the Net Proceeds as set out in the section headed “Future Plans and Use of Proceeds” in the Prospectus. The intended application of the Net Proceeds as stated in the Prospectus and the actual utilisation of the Net Proceeds from the Listing Date up to the date of this interim report is set out below:

**全球發售所得款項用途**

本公司股份於2022年7月12日在聯交所主板上市。本集團從全球發售中獲得現金款項淨額（包括超額配股權的部分行使及經扣除包銷佣金及相關費用和開支）約339.6百萬港元（「**所得款項淨額**」）。本集團將繼續按招股章程「未來計劃及所得款項用途」一節所載方式動用所得款項淨額。自上市日期直至本中期報告日期，招股章程所述所得款項淨額擬定用途及所得款項淨額的實際動用情況如下：

<b>Planned Use of Net Proceeds</b>	<b>Percentage of the Net Proceeds</b>	<b>Actual Allocation of the Net Proceeds</b>	<b>Utilised Net Proceeds as at 30 June 2024</b>	<b>Unutilised balance as at 30 June 2024</b>	<b>Expected timeline for the use of the balance</b>
	佔所得款項淨額的百分比	實際獲分配所得款項淨額	截至2024年6月30日已動用款項	截至2024年6月30日尚未動用的餘額	預期動用餘額的時間
	%	HK\$ million 百萬港元	HK\$ million 百萬港元	HK\$ million 百萬港元	
Upgrade and enhance SaaS products	50.8	172.5	46.4	126.1	By 31 December 2025 2025年12月31日以前
更新及提升SaaS產品					
R&D technology and data warehouse	49.2	167.1	35.5	131.6	By 31 December 2025 2025年12月31日以前
研發技術及數據倉庫					
<b>Total</b>	<b>100%</b>	<b>339.6</b>	<b>81.9</b>	<b>257.7</b>	
<b>合計</b>					

During the Reporting Period, the Net Proceeds have been and will be used in accordance with the purposes set out in the Prospectus, and there has been no material change or delay in the use of the Net Proceeds.

報告期內，所得款項淨額已經及將會根據招股章程所載用途使用，且所得款項淨額用途並無重大變動或延誤。



## 40 UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME 未經審核中期簡明綜合損益及其他全面收益表

For the six months ended 30 June 2024

截至2024年6月30日止六個月

		Notes 附註	2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
<b>REVENUE</b>	<b>收入</b>	5	<b>159,531</b>	144,950
Cost of sales	銷售成本		<b>(70,743)</b>	(69,768)
<b>Gross profit</b>	<b>毛利</b>		<b>88,788</b>	75,182
Other income and gains	其他收入及收益	5	<b>23,454</b>	35,816
Selling and distribution expenses	銷售及分銷開支		<b>(17,184)</b>	(15,109)
Administrative expenses	行政開支		<b>(16,963)</b>	(15,121)
Research and development costs	研發成本		<b>(28,881)</b>	(27,229)
Impairment losses on financial assets, net	金融資產減值虧損淨額		<b>(5,725)</b>	(5,361)
Other expenses	其他開支		<b>(616)</b>	(8)
Finance costs	財務成本		<b>(329)</b>	(278)
<b>PROFIT BEFORE TAX</b>	<b>除稅前溢利</b>	6	<b>42,544</b>	47,892
Income tax expense	所得稅開支	7	<b>(196)</b>	(922)
<b>PROFIT FOR THE PERIOD</b>	<b>期內溢利</b>		<b>42,348</b>	46,970
Attributable to:	以下各項應佔：			
Owners of the parent	母公司擁有人		<b>41,675</b>	47,833
Non-controlling interests	非控股權益		<b>673</b>	(863)
			<b>42,348</b>	46,970
<b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD</b>	<b>期內全面收益總額</b>		<b>42,348</b>	46,970
Attributable to:	以下各項應佔：			
Owners of the parent	母公司擁有人		<b>41,675</b>	47,833
Non-controlling interests	非控股權益		<b>673</b>	(863)
			<b>42,348</b>	46,970
<b>EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT</b>	<b>母公司普通股權益持有人應佔每股盈利</b>			
Basic and diluted	基本及攤薄	9	<b>0.10</b>	0.11

# UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

## 未經審核中期簡明綜合財務狀況表

41

30 June 2024  
2024年6月30日

			<b>30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元</b>	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
		Notes 附註		
<b>NON-CURRENT ASSETS</b>	<b>非流動資產</b>			
Property, plant and equipment	物業、廠房及設備	10	<b>3,981</b>	5,070
Right-of-use assets	使用權資產		<b>12,990</b>	13,490
Other intangible assets	其他無形資產		<b>1,682</b>	1,085
Time deposits	定期存款	13	<b>157,708</b>	165,377
Goodwill	商譽	17	<b>11,551</b>	–
Deferred tax assets	遞延稅項資產		<b>3,511</b>	3,455
Total non-current assets	非流動資產總值		<b>191,423</b>	188,477
<b>CURRENT ASSETS</b>	<b>流動資產</b>			
Inventories	存貨		<b>6,512</b>	1,561
Trade and notes receivables	貿易應收款項及應收票據	11	<b>97,830</b>	90,043
Prepayments, other receivables and other assets	預付款項、其他應收款項及 其他資產		<b>15,459</b>	49,656
Financial assets at fair value through profit or loss	按公平值計入損益的金融資產	12	<b>88,460</b>	–
Due from a related party	應收一名關聯方款項	19	<b>124</b>	45
Time deposits	定期存款	13	<b>388,650</b>	344,028
Cash and cash equivalents	現金及現金等價物	13	<b>23,764</b>	123,931
Total current assets	流動資產總值		<b>620,799</b>	609,264
<b>CURRENT LIABILITIES</b>	<b>流動負債</b>			
Trade payables	貿易應付款項	14	<b>12,835</b>	13,109
Other payables and accruals	其他應付款項及應計費用	15	<b>99,024</b>	63,540
Lease liabilities	租賃負債		<b>4,862</b>	4,211
Due to related parties	應付關聯方款項	19	<b>130</b>	432
Tax payable	應付稅項		<b>1,171</b>	2,969
Total current liabilities	流動負債總額		<b>118,022</b>	84,261

## 42 UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION 未經審核中期簡明綜合財務狀況表

30 June 2024  
2024年6月30日

		30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
		Note 附註	
<b>NET CURRENT ASSETS</b>	流動資產淨值	<b>502,777</b>	525,003
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>	資產總值減流動負債	<b>694,200</b>	713,480
<b>NON-CURRENT LIABILITIES</b>	非流動負債		
Lease liabilities	租賃負債	<b>9,039</b>	10,026
Deferred tax liabilities	遞延稅項負債	<b>3,030</b>	3,000
Total non-current liabilities	非流動負債總額	<b>12,069</b>	13,026
<b>Net assets</b>	資產淨值	<b>682,131</b>	700,454
<b>EQUITY</b>	股權		
<b>Equity attributable to owners of the parent</b>	母公司擁有人應佔股權		
Share capital	股本	16	30,384
Treasury shares	庫存股份	16	<b>(209,344)</b>
Reserves	儲備		852,054
		<b>684,003</b>	703,340
Non-controlling interests	非控股權益	<b>(1,872)</b>	(2,886)
<b>Total equity</b>	總權益	<b>682,131</b>	700,454

# UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

## 未經審核中期簡明綜合權益變動表

43

For the six months ended 30 June 2024  
截至2024年6月30日止六個月

		Attributable to owners of the parent							Non-controlling interest	Total equity
		母公司擁有人應佔								
		Share capital	Treasury shares	Share premium*	Capital reserve*	Statutory reserve*	Retained profits*	Total		
		股本	庫存股份	股份溢價*	資本儲備*	法定儲備*	保留溢利*	總計	非控股權益	總權益
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
At 1 January 2024	於2024年1月1日	30,384	(179,098)	477,339	19,372	38,005	317,338	703,340	(2,886)	700,454
Total comprehensive income for the period	期內全面收入總額	-	-	-	-	-	41,675	41,675	673	42,348
Shares repurchased	購回股份	-	(30,246)	-	-	-	-	(30,246)	-	(30,246)
Capital injection by a non-controlling shareholder	一名非控股股東的注資	-	-	-	-	-	-	-	363	363
Acquisition of a subsidiary (note 17)	收購一間附屬公司(附註17)	-	-	-	-	-	-	-	672	672
Acquisition of non-controlling interests	收購非控股權益	-	-	-	(915)	-	-	(915)	(694)	(1,609)
Dividends declared (note 8)	已宣派股息(附註8)	-	-	-	-	-	(29,851)	(29,851)	-	(29,851)
At 30 June 2024 (unaudited)	於2024年6月30日(未經審核)	30,384	(209,344)	477,339	18,457	38,005	329,162	684,003	(1,872)	682,131

## 44 UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 未經審核中期簡明綜合權益變動表

For the six months ended 30 June 2024

截至2024年6月30日止六個月

		Attributable to owners of the parent 母公司擁有人應佔						Non-controlling interest		Total equity
		Share capital	Treasury shares	Share premium*	Capital reserve*	Statutory reserve*	Retained profits*	Total	Non-controlling interest	Total equity
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
At 1 January 2023	於2023年1月1日	30,384	(101,121)	477,339	19,372	29,556	239,508	695,038	(1,802)	693,236
Total comprehensive income for the period	期內全面收入總額	-	-	-	-	-	47,833	47,833	(863)	46,970
Shares repurchased	購回股份	-	(5,876)	-	-	-	-	(5,876)	-	(5,876)
Dividends declared	已宣派股息	-	-	-	-	-	(15,753)	(15,753)	-	(15,753)
At 30 June 2023 (unaudited)	於2023年6月30日 (未經審核)	30,384	(106,997)	477,339	19,372	29,556	271,588	721,242	(2,665)	718,577

\* These reserve accounts comprise the consolidated reserves of RMB862,963,000 (30 June 2023: RMB797,855,000) in the unaudited interim condensed consolidated statement of financial position as at 30 June 2024.

\* 該等儲備賬包括於2024年6月30日的未經審核中期簡明綜合財務狀況表內的綜合儲備人民幣862,963,000元(2023年6月30日：人民幣797,855,000元)。

# UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

## 未經審核中期簡明綜合現金流量表

45

For the six months ended 30 June 2024

截至2024年6月30日止六個月

			2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
		Notes 附註		
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>	<b>經營活動之現金流量</b>			
Profit before tax	除稅前溢利		<b>42,544</b>	47,892
Adjustments for:	就以下各項調整：			
Finance costs	財務成本		<b>329</b>	278
Bank interest income	銀行利息收入	5	<b>(13,450)</b>	(12,521)
Investment income from financial assets at fair value through profit or loss	按公平值計入損益的金融資產的投資收入	5	<b>(119)</b>	(20)
Fair value losses/(gains) on financial assets at fair value through profit or loss	按公平值計入損益的金融資產公平值虧損/(收益)	5	<b>575</b>	(209)
Depreciation of property, plant and equipment	物業、廠房及設備折舊	10	<b>1,277</b>	1,242
Depreciation of right-of-use assets	使用權資產折舊		<b>2,326</b>	2,890
Amortisation of other intangible assets	其他無形資產攤銷		<b>364</b>	430
Gains on lease modifications	租賃修改收益	5	<b>(11)</b>	(14)
Impairment of trade receivables	貿易應收款項減值	11	<b>5,725</b>	5,361
Foreign exchange gains, net	外匯收益淨額	5	<b>(2,291)</b>	(14,445)
Losses on disposal of items of property, plant and equipment	出售物業、廠房及設備項目的虧損	6	<b>9</b>	1
(Increase)/decrease in trade and notes receivables	貿易應收款項及應收票據(增加)/減少		<b>(12,761)</b>	12,864
(Increase)/decrease in prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產(增加)/減少		<b>(1,142)</b>	569
Increase in due from a related party	應收一名關聯方款項增加		<b>(79)</b>	-
Increase in inventories	存貨增加		<b>(4,897)</b>	(1,043)
Decrease in due to related parties	應付關聯方款項減少		<b>(302)</b>	(198)
Decrease in trade payables	貿易應付款項減少		<b>(2,076)</b>	(5,676)
Increase in other payables and accruals	其他應付款項及應計費用增加		<b>5,444</b>	13,743
Cash generated from operations	經營所得現金		<b>21,465</b>	51,144
Interest received	已收利息		<b>191</b>	3,485
Income tax paid	已付所得稅		<b>(2,095)</b>	(7,171)
Net cash flows from operating activities	經營活動所得現金流量淨額		<b>19,561</b>	47,458

## 46 UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

### 未經審核中期簡明綜合現金流量表

For the six months ended 30 June 2024

截至2024年6月30日止六個月

		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>	<b>投資活動之現金流量</b>		
Purchases of items of property, plant and equipment and related advance payments	購買物業、廠房及設備項目以及相關墊款付款	<b>(155)</b>	(1,594)
Proceeds from disposals of items of property, plant and equipment	出售物業、廠房及設備項目所得款項	<b>12</b>	1
Additions to other intangible assets	其他無形資產添置	<b>(324)</b>	(94)
Purchases of financial assets at fair value through profit or loss	購買按公平值計入損益的金融資產	<b>(121,490)</b>	(49,000)
Proceeds from disposal of financial assets at fair value through profit or loss	出售按公平值計入損益的金融資產所得款項	<b>33,961</b>	4,510
Acquisition of a subsidiary	收購一間附屬公司	<b>(11,972)</b>	-
Purchases of time deposits	購買定期存款	<b>(136,781)</b>	(210,020)
Proceeds from disposal of time deposits	出售定期存款所得款項	<b>110,365</b>	-
Interest income received from time deposits	定期存款獲得的利息收入	<b>4,602</b>	-
Investment income received from financial assets at fair value through profit or loss	按公平值計入損益的金融資產獲得的投資收入	<b>119</b>	20
Net cash flows used in investing activities	投資活動所用現金流量淨額	<b>(121,663)</b>	(256,177)

# UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

## 未經審核中期簡明綜合現金流量表

47

For the six months ended 30 June 2024

截至2024年6月30日止六個月

		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>	<b>融資活動之現金流量</b>		
Principal portion of lease payments	租賃付款的本金部分	(2,151)	(2,365)
Interest paid for lease liabilities	就租賃負債支付利息	(329)	(278)
Acquisition of non-controlling interests	收購非控股權益	(1,609)	-
Repayment of repurchase of shares	償還購回股份	5,250	-
Capital injection by a non-controlling shareholder	一名非控股股東的注資	363	-
Repurchase of shares	購回股份	-	(5,471)
Net cash flows from/(used in) financing activities	融資活動所得/(所用)現金流量淨額	1,524	(8,114)
<b>NET DECREASE IN CASH AND CASH EQUIVALENTS</b>	<b>現金及現金等價物減少淨額</b>	<b>(100,578)</b>	<b>(216,833)</b>
Cash and cash equivalents at beginning of period	期初現金及現金等價物	123,931	409,318
Effect of foreign exchange rate changes, net	外匯匯率變動影響淨額	411	6,709
<b>CASH AND CASH EQUIVALENTS AT END OF PERIOD</b>	<b>期末現金及現金等價物</b>	<b>23,764</b>	<b>199,194</b>
<b>ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS</b>	<b>現金及現金等價物結餘分析</b>		
Cash and bank balances	現金及銀行結餘	23,764	199,194
Cash and cash equivalents as stated in the interim condensed consolidated statement of financial position and the interim condensed consolidated statements of cash flow	於中期簡明綜合財務狀況表及中期簡明綜合現金流量表列賬的現金及現金等價物	<b>23,764</b>	<b>199,194</b>



## 48 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 未經審核中期簡明綜合財務資料附註

### 1. CORPORATE INFORMATION

The Company is a limited liability company incorporated in the Cayman Islands on 4 March 2019. The registered address of the Company is at the office of Ogier Global (Cayman) Limited, of 89 Nexus Way, Grand Cayman, KY1-9009, Cayman Islands.

The Company is an investment holding company. During the reporting period, the Company's subsidiaries were principally engaged in the provision of Data Insight Solutions, Data-driven Publications and Events and SaaS products.

The shares of the Company were listed on the Main Board of The Stock Exchange of Hong Kong Limited on 12 July 2022.

### 2. BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2024 has been prepared in accordance with Hong Kong Accounting Standard ("HKAS") 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2023.

### 1. 公司資料

本公司為一間於2019年3月4日於開曼群島註冊成立的有限公司。本公司的註冊地址位於Ogier Global (Cayman) Limited的辦事處，即89 Nexus Way, Grand Cayman, KY1-9009, Cayman Islands。

本公司為投資控股公司。於報告期，本公司的附屬公司主要從事提供數據洞察解決方案、數據驅動發佈及活動以及SaaS產品。

本公司股份於2022年7月12日在香港聯交所主板上市。

### 2. 編製基準

截至2024年6月30日止六個月的中期簡明綜合財務資料乃根據香港會計準則（「香港會計準則」）第34號*中期財務報告*編製。中期簡明綜合財務資料並不包括年度財務報表規定須予披露之所有資料及披露資料，並應與本集團截至2023年12月31日止年度的年度綜合財務報表一併閱讀。

# NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 未經審核中期簡明綜合財務資料附註

### 3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2023, except for the adoption of the following revised Hong Kong Financial Reporting Standards ("HKFRSs") for the first time for the current period's financial information.

Amendments to HKFRS 16  
香港財務報告準則  
第16號(修訂本)

Amendments to HKAS 1

香港會計準則第1號(修訂本)

Amendments to HKAS 1

香港會計準則第1號(修訂本)

Amendments to HKAS 7  
and HKFRS 7

香港會計準則第7號及香港財務  
報告準則第7號(修訂本)

*Lease Liability in a Sale and Leaseback*  
售後租回中的租賃負債

*Classification of Liabilities as Current or Non-current*  
(the "2020 Amendments")

將負債分類為流動或非流動(「2020年修訂本」)

*Non-current Liabilities with Covenants (the "2022 Amendments")*

具契諾之非流動負債(「2022年修訂本」)

*Supplier Finance Arrangements*

供應商融資安排

The nature and impact of the revised HKFRSs are described below:

- (a) Amendments to HKFRS 16 specify the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction to ensure the seller-lessee does not recognise any amount of the gain or loss that relates to the right of use it retains. Since the Group has no sale and leaseback transactions with variable lease payments that do not depend on an index or a rate occurring from the date of initial application of HKFRS 16, the amendments did not have any impact on the financial position or performance of the Group.

### 3. 會計政策及披露事項變動

編製中期簡明綜合財務資料所採納的會計政策與編製本集團截至2023年12月31日止年度的年度綜合財務報表所採納者一致，惟本期間的財務資料首次採納以下經修訂香港財務報告準則(「香港財務報告準則」)除外。

經修訂香港財務報告準則的性質及影響如下文所述：

- (a) 香港財務報告準則第16號(修訂本)訂明賣方一承租人計量售後租回交易產生的租賃負債所使用的規定，以確保賣方一承租人不會確認與所保留使用權有關的任何損益金額。由於本集團自首次應用香港財務報告準則第16號之日起，概不存在任何視乎指數或比率而定的可變租賃付款售後租回交易，故修訂本對本集團的財務狀況或表現概無任何影響。

50 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION  
未經審核中期簡明綜合財務資料附註**3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (continued)**

- (b) The 2020 Amendments clarify the requirements for classifying liabilities as current or non-current, including what is meant by a right to defer settlement and that a right to defer must exist at the end of the reporting period. Classification of a liability is unaffected by the likelihood that the entity will exercise its right to defer settlement. The amendments also clarify that a liability can be settled in its own equity instruments, and that only if a conversion option in a convertible liability is itself accounted for as an equity instrument would the terms of a liability not impact its classification. The 2022 Amendments further clarify that, among covenants of a liability arising from a loan arrangement, only those with which an entity must comply on or before the reporting date affect the classification of that liability as current or non-current. Additional disclosures are required for non-current liabilities that are subject to the entity complying with future covenants within 12 months after the reporting period.

The Group has reassessed the terms and conditions of its liabilities as at 1 January 2023 and 2024 and concluded that the classification of its liabilities as current or non-current remained unchanged upon initial application of the amendments. Accordingly, the amendments did not have any impact on the financial position or performance of the Group.

**3. 會計政策及披露事項變動(續)**

- (b) 2020年修訂本澄清將負債分類為流動或非流動的要求，其中包含延遲結算權利的涵義及延遲權利須於報告期末發生。實體將行使其延遲權利的可能性不會影響負債的分類。該等修訂本亦澄清負債可於其自身的股本工具中結算，且僅當可轉換負債中的轉換期權其本身作為股本工具入賬時，負債的條款方才不會影響其分類。2022年修訂本進一步澄清，在貸款安排產生的負債契諾中，僅實體須於報告日期或之前遵守的契諾才會影響該負債分類為流動或非流動。對於因實體須於報告日期後12個月內遵守日後契諾而產生的非流動負債，應作出額外披露。

本集團對2023年1月1日及2024年1月1日之負債條款及條件進行重新評估，並得出結論，於首次應用修訂本後，其負債的流動或非流動分類保持不變。因此，修訂本對本集團的財務狀況或表現概無任何影響。

# NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 未經審核中期簡明綜合財務資料附註

### 3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (continued)

- (c) Amendments to HKAS 7 and HKFRS 7 clarify the characteristics of supplier finance arrangements and require additional disclosure of such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity's liabilities, cash flows and exposure to liquidity risk. The disclosure of relevant information for supplier finance arrangements is not required for any interim reporting period during the first annual reporting period in which an entity applies the amendments. As the Group does not have supplier finance arrangements, the amendments did not have any impact on the interim condensed consolidated financial information.

### 3. 會計政策及披露事項變動(續)

- (c) 香港會計準則第7號及香港財務報告準則第7號(修訂本)澄清供應商融資安排之特點，並要求就此等安排作出進一步披露。修訂本中的披露要求旨在幫助財務報表使用者了解供應商融資安排對實體負債、現金流量及流動性風險敞口的影響。在實體應用修訂本的首個年度報告期間，於任何中期報告期間均無需披露供應商融資安排的相關資料。由於本集團並無供應商融資安排，故該等修訂本對中期簡明綜合財務資料概無任何影響。

## 52 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 未經審核中期簡明綜合財務資料附註

### 4. OPERATING SEGMENT INFORMATION

For management purposes, the Group is not organised into business units based on their services and only has one reportable operating segment. Management monitors the operating results of the Group's operating segment as a whole for the purpose of making decisions about resource allocation and performance assessment.

### 5. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

### 4. 經營分部資料

就管理而言，本集團並無按其服務劃分業務單位，並僅有一個可呈報經營分部。管理層對本集團經營分部的經營業績進行全盤監控，以就資源分配及績效評估作出決策。

### 5. 收入、其他收入及收益

收入分析如下：

	For the six months ended 30 June	
	截至6月30日止六個月	
	2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Revenue from contracts with customers 客戶合約收入	159,531	144,950

# NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 未經審核中期簡明綜合財務資料附註

### 5. REVENUE, OTHER INCOME AND GAINS (continued)

#### Revenue from contracts with customers

(a) Disaggregated revenue information

#### 客戶合約收入

(a) 分類收入資料

		For the six months ended 30 June	
		截至6月30日止六個月	
		2024	2023
		2024年	2023年
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
		RMB'000	RMB'000
		人民幣千元	人民幣千元
<b>Type of goods or services by product categories</b>	<b>按產品類型劃分的貨品或服務類別</b>		
Data Insight Solutions	數據洞察解決方案	84,012	88,692
Data-driven Publications and Events	數據驅動發佈及活動	38,812	32,107
SaaS products	SaaS 產品	36,707	24,151
Total	總計	159,531	144,950
<b>Type of goods or services by application scenarios</b>	<b>按應用場景劃分的貨品或服務類別</b>		
Smart Decision Cloud	智慧決策雲	68,233	72,073
Smart Retail Cloud	智慧零售雲	56,437	43,834
Smart Medical Cloud	智慧醫療雲	17,967	23,314
Smart Health Management Cloud	智慧健康管理雲	16,894	5,729
Total	總計	159,531	144,950
<b>Geographical markets</b>	<b>地理市場</b>		
Chinese Mainland	中國內地	159,003	144,782
Overseas	海外	528	168
Total	總計	159,531	144,950
<b>Timing of revenue recognition</b>	<b>收入確認的時間</b>		
Services transferred at a point in time	於某一時間點轉移的服務	79,935	78,426
Services transferred over time	隨時間轉移的服務	79,596	66,524
Total	總計	159,531	144,950

## 54 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 未經審核中期簡明綜合財務資料附註

### 5. REVENUE, OTHER INCOME AND GAINS (continued)

#### Revenue from contracts with customers (continued)

##### (b) Performance obligations

Information about the Group's performance obligations is summarised below:

##### *Data Insight Solutions*

The performance obligation for delivery of customised research reports is generally satisfied at the point of time when the individual research report is delivered and accepted by the customers and payment is generally due within 120 days from the date of billing. The performance obligation for provision of individual marketing solution is satisfied over time as services are rendered and payment in advance is normally required.

##### *Data-driven Publications and Events*

The performance obligation is satisfied over time as services are rendered, where payment in advance is normally required. The services related to Data-driven Publications and Events are generally completed within one week.

##### *SaaS products*

The performance obligation for granting right to access the proprietary cloud-based software is satisfied over time as services are rendered, where payment in advance is normally required. The performance obligation for API use is satisfied at the point of time when the right to use is granted and payment is generally due immediately. The performance obligation for application software development is satisfied at the point of time when the application software together with relevant license is accepted by the customers, and payment is generally due when the service was completed.

### 5. 收入、其他收入及收益(續)

#### 客戶合約收入(續)

##### (b) 履約責任

有關本集團履約責任的資料概述如下：

##### *數據洞察解決方案*

交付量身定制的研究報告的履約責任一般於個別研究報告交付並獲客戶接納時達成，付款一般自發票日期起 120 日內到期。提供個別營銷解決方案的履約責任隨著提供服務的時間達成，且一般須提前付款。

##### *數據驅動發佈及活動*

履約責任隨著提供服務的時間達成，惟一般須提前付款。與數據驅動發佈及活動相關的服務一般於一星期內完成。

##### *SaaS 產品*

授權接入專有雲端軟件的履約責任隨時間於提供服務時達成，在此情況下一般要求提前付款。使用 API 的履約責任於授出使用權的時間點履行，且通常要求即時付款。應用軟件開發的履約責任於應用軟件連同相關學科組獲客戶接受的時間點達成，而付款通常於服務完成時到期。

# NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 未經審核中期簡明綜合財務資料附註

### 5. REVENUE, OTHER INCOME AND GAINS (continued)

An analysis of other income and gains is as follows:

其他收入及收益的分析如下：

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
<b>Other income</b>	<b>其他收入</b>		
Bank interest income	銀行利息收入	13,450	12,521
Government grants*	政府補助*	7,578	8,206
Investment income from financial assets at fair value through profit or loss	按公平值計入損益的金融資產的投資收入	119	20
Others	其他	5	227
<b>Total other income</b>	<b>其他收入總額</b>	<b>21,152</b>	<b>20,974</b>
<b>Gains</b>	<b>收益</b>		
Fair value gains on financial assets at fair value through profit or loss	按公平值計入損益的金融資產的公平值收益	—	209
Foreign exchange gains, net	匯兌收益淨額	2,291	14,445
Gains on lease modifications	租賃修改收益	11	14
Others	其他	—	174
<b>Total gains</b>	<b>收益總額</b>	<b>2,302</b>	<b>14,842</b>
<b>Total other income and gains</b>	<b>其他收入及收益總額</b>	<b>23,454</b>	<b>35,816</b>

\* The government grants mainly represent incentives awarded by the local governments to support the Group's operation. There were no unfulfilled conditions or contingencies attached to these grants.

\* 政府補助主要指獲當地政府授予的獎勵，以支持本集團營運。該等獎勵並無附帶未履行條件或或然事項。



## 56 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 未經審核中期簡明綜合財務資料附註

### 6. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

### 6. 除稅前溢利

本集團的除稅前溢利於扣除／(計入)以下各項後達致：

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Cost of services provided	提供服務成本	<b>70,743</b>	69,768
Depreciation of property, plant and equipment	物業、廠房及設備折舊	<b>1,277</b>	1,242
Depreciation of right-of-use assets	使用權資產折舊	<b>2,326</b>	2,890
Amortisation of other intangible assets	其他無形資產攤銷	<b>364</b>	430
Research and development costs	研發成本	<b>28,881</b>	27,229
Lease payments not included in the measurement of lease liabilities	不計入租賃負債計量的 租賃付款	<b>66</b>	50
Bank interest income	銀行利息收入	<b>(13,450)</b>	(12,521)
Government grants	政府補助	<b>(7,578)</b>	(8,206)
Investment income from financial assets at fair value through profit or loss	按公平值計入損益 的金融資產的投資收入	<b>(119)</b>	(20)
Fair value losses/(gains) on financial assets at fair value through profit	按公平值計入損益 的金融資產的公平值 虧損／(收益)	<b>575</b>	(209)
Gains on lease modifications	租賃修改收益	<b>(11)</b>	(14)
Foreign exchange gains, net	匯兌收益淨額	<b>(2,291)</b>	(14,445)
Losses on disposal of items of property, plant and equipment	出售物業、廠房及設備 項目之虧損	<b>9</b>	1
Impairment of trade receivables, net	貿易應收款項減值淨額	<b>5,725</b>	5,361

# NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 未經審核中期簡明綜合財務資料附註

### 7. INCOME TAX

The Group is subject to income tax on an entity basis on profit arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Pursuant to the rules and regulations of the Cayman Islands and the BVI, the Company and its subsidiary are not subject to any income tax in the Cayman Islands and the BVI.

The statutory tax rate for the subsidiary in Hong Kong is 16.5%. No Hong Kong profits tax on the subsidiary has been provided as there was no assessable profit arising in Hong Kong during the period.

The provision for current income tax in Chinese Mainland is based on a statutory tax rate of 25% of the assessable profits of the PRC subsidiaries of the Group as determined in accordance with the PRC Corporate Income Tax Law.

Zhongkang Technology was accredited as a high and new technology enterprise ("HNTE") in 2022, and the certifications were valid for three years. For the six months ended 30 June 2024, Zhongkang Technology was entitled to a preferential PRC Corporate Income tax rate of 15% (30 June 2023: 15%).

### 7. 所得稅

本集團須就本集團成員公司所處及經營所在司法權區產生或賺取的溢利，按實體基準繳納所得稅。

根據開曼群島及英屬處女群島的規則及法規，本公司及其附屬公司毋須於開曼群島及英屬處女群島繳納任何所得稅。

香港附屬公司的法定稅率為16.5%。由於期內並無於香港產生應課稅溢利，故並無就附屬公司計提香港利得稅撥備。

中國內地即期所得稅撥備乃按根據中國企業所得稅法釐定的本集團中國附屬公司的應課稅溢利按法定稅率25%釐定。

中康科技於2022年被認定為高新技術企業（「HNTE」），證書有效期為三年。截至2024年6月30日止六個月，中康科技享有15%的優惠中國企業所得稅稅率（2023年6月30日：15%）。

## 58 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 未經審核中期簡明綜合財務資料附註

### 7. INCOME TAX (continued)

Certain of the subsidiaries, which operate in Chinese Mainland, are identified as Small and Micro Enterprises and were entitled to a preferential tax rate of 5% during the period.

The major components of the income tax expense of the Group during the period are analysed as follows:

### 7. 所得稅(續)

於期內，於中國內地營運的若干附屬公司被認定為小微企業，享有5%的優惠稅率。

本集團於期內的所得稅開支主要組成部分分析如下：

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Current - Chinese Mainland charge for the period	即期一期內扣除的中國內地稅項	254	3,403
Deferred tax	遞延稅項	(58)	(2,481)
Total tax charge for the period	期內扣除的稅項總額	196	922

### 8. DIVIDENDS

On 28 March 2024, a final dividend for the year ended 31 December 2023 of HK\$7.25 cents per ordinary share, amounting to approximately RMB29,851,000, has been approved by the shareholders at the annual general meeting for the Company.

The board of directors did not declare the payment of an interim dividend for the six months ended 30 June 2024 (six months ended 30 June 2023: Nil).

### 8. 股息

於2024年3月28日，本公司股東於股東週年大會上批准派發截至2023年12月31日止年度的末期股息每股普通股7.25港仙，共計約人民幣29,851,000元。

董事會並無宣派截至2024年6月30日止六個月的中期股息(截至2023年6月30日止六個月：無)。

# NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 未經審核中期簡明綜合財務資料附註

### 9. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amounts is based on the profit for the period attributable to ordinary equity holders of the parent.

The Group had no potentially dilutive ordinary shares in issue during the period.

The calculations of basic and diluted earnings per share are based on:

### 9. 母公司普通股權益持有人應佔每股盈利

每股基本盈利金額乃根據母公司普通股權益持有人應佔期內溢利計算。

期內本集團並無潛在攤薄已發行普通股。

每股基本及攤薄盈利乃根據以下數據計算：

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
<b>Earnings</b>	<b>盈利</b>		
Profit attributable to ordinary equity holders of the parent, used in the basic and diluted earnings per share calculation	用於計算每股基本及攤薄盈利的母公司普通股權益持有人應佔溢利	<b>41,675</b>	47,833

60 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION  
未經審核中期簡明綜合財務資料附註

9. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (continued) 9. 母公司普通股權益持有人應佔每股盈利(續)

		Number of shares For the six months ended 30 June 股份數目 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核)	2023 2023年 (Unaudited) (未經審核)
<b>Shares</b>	<b>股份</b>		
Weighted average number of ordinary shares in issue used in the basic and diluted earnings per share calculation	用於計算每股基本及攤薄盈利的已發行普通股加權平均數	<b>417,249,077</b>	430,762,185

10. PROPERTY, PLANT AND EQUIPMENT 10. 物業、廠房及設備

		30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Net carrying amount at beginning of period/year	於期/年初的賬面值	<b>5,070</b>	4,383
Additions	添置	<b>155</b>	3,118
Acquisition of a subsidiary (note 17)	收購一間附屬公司 (附註17)	<b>54</b>	—
Depreciation provided during the period/year	期/年內計提折舊	<b>(1,277)</b>	(2,427)
Disposals	出售	<b>(21)</b>	(4)
Net carrying amount at end of period/year	於期/年末的賬面淨值	<b>3,981</b>	5,070

# NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 未經審核中期簡明綜合財務資料附註

### 11. TRADE AND NOTES RECEIVABLES

### 11. 貿易應收款項及應收票據

		<b>30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元</b>	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Trade receivables	貿易應收款項	<b>125,230</b>	111,351
Notes receivable	應收票據	<b>1,855</b>	2,222
Impairment	減值	<b>(29,255)</b>	(23,530)
<b>Total</b>	<b>總計</b>	<b>97,830</b>	90,043

The Group's trading terms with its customers are mainly on credit. The credit terms granted generally ranged from 7 days to 120 days, depending on the specific payment terms in each contract. The Group seeks to maintain strict control over its outstanding receivables. Overdue balances are reviewed regularly by senior management. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

本集團與其客戶的貿易條款以信貸為主。所授出的信貸期一般介乎7日至120日，視乎各份合約的特定支付條款而定。本集團尋求維持嚴格控制其未償還應收款項。高級管理層定期檢討逾期結餘。本集團並未就貿易應收款項結餘持有任何抵押品或其他信用增強措施。貿易應收款項不計息。

## 62 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 未經審核中期簡明綜合財務資料附註

### 11. TRADE AND NOTES RECEIVABLES (continued) 11. 貿易應收款項及應收票據(續)

An ageing analysis of the trade receivables as at the end of the reporting period, based on the transaction dates and net of loss allowance, is as follows:

於報告期末，貿易應收款項基於交易日期及扣除虧損撥備後的賬齡分析如下：

		<b>30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元</b>	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Within 6 months	6個月內	<b>77,824</b>	67,147
6 to 12 months	6至12個月	<b>9,653</b>	11,653
1 to 2 years	1至2年	<b>7,868</b>	8,268
2 to 3 years	2至3年	<b>630</b>	753
<b>Total</b>	<b>總計</b>	<b>95,975</b>	87,821

The movements in the loss allowance for impairment of trade receivables are as follows:

貿易應收款項的減值虧損撥備變動如下：

		<b>30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元</b>	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
At beginning of period/year	於期／年初	<b>23,530</b>	6,322
Impairment losses, net	減值虧損淨額	<b>5,725</b>	17,607
Amount written off as uncollectible	因不可收回而撇銷的金額	-	(399)
<b>At end of period/year</b>	<b>於期／年末</b>	<b>29,255</b>	23,530

NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION  
未經審核中期簡明綜合財務資料附註

**12. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS**      **12. 按公平值計入損益的金融資產**

		<b>30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元</b>	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Unlisted investments, at fair value	非掛牌投資， 按公平值計值	<b>88,460</b>	-

The unlisted investments represented certain financial products issued by commercial banks in Chinese Mainland, a wealth management product issued by a portfolio company in Chinese Mainland and the unlisted equity investment at fair value through profit or loss. They were classified as financial assets at fair value through profit or loss as their contractual cash flows are not solely payments of principal and interest.

非掛牌投資指中國內地商業銀行發行的若干金融產品、中國內地產品組合公司上市一款理財產品及按公平值計入損益的非上市股權投資。由於該等投資的合約現金流量並非僅支付本金及利息，故被分類為按公平值計入損益的金融資產。



64 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION  
未經審核中期簡明綜合財務資料附註

## 13. CASH AND CASH EQUIVALENTS

## 13. 現金及現金等價物

		<b>30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元</b>	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Cash and bank balances	現金及銀行結餘	<b>19,214</b>	61,804
Time deposits	定期存款	<b>550,908</b>	571,532
Subtotal	小計	<b>570,122</b>	633,336
Less:	減：		
Current portion:	即期部分：		
Non-pledged time deposits with original maturity of over three months when required	於取得時原到期日長於三個月之無抵押定期存款	<b>(388,650)</b>	(344,028)
Non-Current portion	非即期部分：		
Non-pledged time deposits with original maturity of over three months when required	於取得時原到期日長於三個月之無抵押定期存款	<b>(157,708)</b>	(165,377)
Cash and cash equivalents	現金及現金等價物	<b>23,764</b>	123,931
Denominated in:	以下列貨幣計值：		
RMB	人民幣	<b>13,569</b>	90,220
US\$	美元	<b>10,134</b>	33,475
SGD	新加坡元	<b>2</b>	141
HK\$	港元	<b>59</b>	95
Cash and cash equivalents	現金及現金等價物	<b>23,764</b>	123,931

# NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 未經審核中期簡明綜合財務資料附註

### 13. CASH AND CASH EQUIVALENTS (continued)

The RMB is not freely convertible into other currencies, however, under Chinese Mainland's Foreign Exchange Control Regulations and Administration of Settlement, and Sale and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorised to conduct foreign exchange business.

Cash at banks earns interest at floating rates based on daily bank deposit rates. Time deposits are made for varying periods from three months to three years and earn interest at the fixed time deposit rates. The bank balances and time deposits are deposited with creditworthy banks with no recent history of default.

### 14. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

		<b>30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元</b>	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Within 3 months	於3個月內	<b>7,877</b>	11,128
4 to 6 months	4至6個月	<b>3,755</b>	366
7 to 12 months	7至12個月	<b>321</b>	1,326
Over 12 months	12個月以上	<b>882</b>	289
<b>Total</b>	<b>總計</b>	<b>12,835</b>	13,109

Trade payables are non-interest-bearing and are normally settled within 90 days.

### 13. 現金及現金等價物(續)

人民幣不可自由兌換為其他貨幣，然而，根據中國內地《外匯管理條例》及《結匯、售匯及付匯管理規定》，本集團獲准透過獲授權進行外匯業務的銀行將人民幣兌換為其他貨幣。

銀行現金按基於每日銀行存款利率的浮動利率賺取利息。定期存款就三個月至三年的不同期間敘造，並按固定的定期存款利率賺取利息。銀行結餘及定期存款存入近期並無違約歷史的信譽良好的銀行。

### 14. 貿易應付款項

於報告期末，基於發票日期的貿易應付款項賬齡分析如下：

貿易應付款項為不計息，一般於90日內結清。

66 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION  
未經審核中期簡明綜合財務資料附註

## 15. OTHER PAYABLES AND ACCRUALS

## 15. 其他應付款項及應計費用

		<b>30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元</b>	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Payroll payables	應付薪酬	<b>9,513</b>	26,497
Contract liabilities	合約負債	<b>49,293</b>	28,698
Tax payables other than income tax	應付稅項(所得稅除外)	<b>7,757</b>	4,379
Dividend payable	應付股息	<b>29,851</b>	–
Other payables	其他應付款項	<b>2,610</b>	3,966
<b>Total</b>	<b>總計</b>	<b>99,024</b>	63,540

Contract liabilities include short-term advances received before the services are rendered.

合約負債包括提供服務前收取的短期預付款項。

NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 67  
 未經審核中期簡明綜合財務資料附註

16. SHARE CAPITAL AND TREASURY SHARES 16. 股本及庫存股份

		<b>30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元</b>	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Authorised:	法定：		
2,000,000,000 (2023: 2,000,000,000) ordinary shares of US\$0.01 each	2,000,000,000 股 (2023年： 2,000,000,000 股) 每股面值0.01美元 的普通股		
US\$'000	千美元	<b>20,000</b>	20,000
Issued and fully paid:	已發行及繳足：		
451,770,000 (2023: 451,770,000) ordinary shares of US\$0.01 each	451,770,000 股 (2023年： 451,770,000 股) 每股面值0.01美元 的普通股		
US\$'000	千美元	<b>4,518</b>	4,518
RMB'000	人民幣千元	<b>30,384</b>	30,384

## 68 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 未經審核中期簡明綜合財務資料附註

### 16. SHARE CAPITAL AND TREASURY SHARES (continued) 16. 股本及庫存股份(續)

A summary of movements in the Company's share capital is as follows:

本公司股本的變動概要如下：

		Notes 附註	Number of shares in issue 已發行 股份數目	Share capital 股本 RMB'000 人民幣千元	Treasury shares 庫存股份 RMB'000 人民幣千元
At 1 January 2023	於 2023 年 1 月 1 日		451,770,000	30,384	(101,121)
Shares repurchased	購回股份	(a)	–	–	(77,977)
At 31 December 2023 and 1 January 2024	於 2023 年 12 月 31 日 及 2024 年 1 月 1 日		451,770,000	30,384	(179,098)
Shares repurchased	購回股份	(b)	–	–	(30,246)
At 30 June 2024	於 2024 年 6 月 30 日		451,770,000	30,384	(209,344)

# NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 未經審核中期簡明綜合財務資料附註

### 16. SHARE CAPITAL AND TREASURY SHARES (continued)

Notes:

- (a) In 2023, the Company purchased 16,228,000 of its shares on the Stock Exchange at a total consideration of approximately HK\$86,459,000 (equivalent to approximately RMB77,977,000) for a share award scheme.
- (b) In 2024, the Company purchased 5,878,500 of its shares on the Stock Exchange at a total consideration of approximately HK\$33,398,000 (equivalent to approximately RMB30,246,000) for a share award scheme.

### 17. BUSINESS COMBINATION

On 5 February 2024, Guangzhou Sinohealth Information Co., Ltd. and Foshan Heheng Equity Investment Partnership (Limited Partnership), a non-wholly owned partnership of Mr. Wu Yushu and Ms. Wang Lifang, the executive directors of the Company, entered into an equity transfer agreement and a partnership property share transfer agreement for the acquisition of 50.6% equity interests in Guangzhou Zhonghui Medical Technology Company Limited (“**Zhonghui Medical**”) at a consideration of RMB12,239,000. On 3 April 2024, the Company completed the acquisition of Zhonghui Medical, which was settled by cash of RMB12,239,000. Upon completion of the acquisition, Zhonghui Medical became an indirect non-wholly owned subsidiary of the Company.

### 16. 股本及庫存股份(續)

附註：

- (a) 2023年，本公司就股份獎勵計劃，按總代價約86,459,000港元(相當於約人民幣77,977,000元)在聯交所購回16,228,000股股份。
- (b) 2024年，本公司就股份獎勵計劃，按總代價約33,398,000港元(相當於約人民幣30,246,000元)在聯交所購回5,878,500股股份。

### 17. 業務合併

於2024年2月5日，廣州中康資訊股份有限公司與佛山合恒股權投資合夥企業(有限合夥)(為本公司執行董事吳鬱抒先生及王莉芳女士的非全資合夥企業)就收購廣州中惠醫療科技有限公司(「**中惠醫療**」)50.6%股權訂立股權轉讓協議和合夥企業財產份額轉讓協議，收購代價為人民幣12,239,000元。於2024年4月3日，本公司完成收購中惠醫療，該收購以現金人民幣12,239,000元結算。收購完成後，中惠醫療成為本公司的間接非全資附屬公司。

## 70 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 未經審核中期簡明綜合財務資料附註

### 17. BUSINESS COMBINATION (continued)

The fair values of the identifiable assets and liabilities of Zhonghui Medical as at the date of acquisition were as follows:

### 17. 業務合併(續)

中惠醫療於收購日期的可識別資產及負債之公平值如下：

		Fair value recognized on acquisition 於收購中確認 的公平值 RMB'000 人民幣千元 (Unaudited) (未經審核)
Property, plant and equipment	物業、廠房及設備	54
Patents and licences	專利及證書	637
Right-of-use assets	使用權資產	896
Cash and bank balances	現金及銀行結餘	267
Inventories	存貨	54
Trade and notes receivables	貿易應收款項及應收票據	751
Prepayments and other receivables	預付款項及其他應收款項	114
Financial assets at fair value through profit or loss	按公平值計入損益的金融資產	1,506
Trade payables	貿易應付款項	(1,802)
Other payables and accruals	其他應付款項及應計費用	(189)
Lease liabilities	租賃負債	(896)
Deferred tax liabilities	遞延稅項負債	(32)
Total identifiable net assets at fair value	按公平值計量之可識別資產 淨值總額	1,360
Non-controlling interests	非控股權益	(672)
Goodwill on acquisition	收購商譽	11,551
Satisfied by cash	以現金結算	12,239

# NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 未經審核中期簡明綜合財務資料附註

### 17. BUSINESS COMBINATION (continued)

The fair values of the trade receivables and other receivables as at the date of acquisition amounted to RMB751,000 and RMB114,000, respectively. The gross contractual amounts of trade receivables and other receivables were RMB751,000 and RMB114,000, respectively, of which the full contractual amounts are expected to be collectible.

The goodwill of RMB11,551,000 recognised above comprises a set of copyrights of Multi-disciplinary Treatment (MDT) collaboration software and the value of benefits arising from the acquisition which are neither separable nor contractual and therefore do not meet the criteria for recognition as intangible assets under HKAS 38 *Intangible Assets*. None of the goodwill recognised is expected to be deductible for income tax purposes.

Since the acquisition, Zhonghui Medical has contributed RMB5,170,000 to the Group's revenue and RMB589,000 to the consolidated profit for the six months ended 30 June 2024.

Had the combination taken place at the beginning of the year, the revenue from continuing operations of the Group and the profit of the Group for the year would have been RMB161,778,000 and RMB42,600,000, respectively.

### 17. 業務合併(續)

貿易應收款項及其他應收款項於收購日期之公平值分別為人民幣751,000元及人民幣114,000元。貿易應收款項及其他應收款項的合約款項總額分別為人民幣751,000元及人民幣114,000元，合約款項預計可全數收回。

上文已確認的商譽人民幣11,551,000元包括一系列多學科治療(MDT)合作軟件及收購產生之並非獨立或合約性質的利益價值，故根據香港會計準則第38號無形資產，並不符合確認為無形資產的標準。概無已確認商譽預期就所得稅目的而可予扣減。

自收購以來，中惠醫療已對本集團收入貢獻人民幣5,170,000元，並對截至2024年6月30日止六個月的綜合溢利貢獻人民幣589,000元。

倘若合併於年初進行，則本集團持續經營所得收入及本集團年度溢利將分別為人民幣161,778,000元及人民幣42,600,000元。



## 72 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 未經審核中期簡明綜合財務資料附註

### 17. BUSINESS COMBINATION (continued)

The assessment of the fair value of the identifiable assets and liabilities of Zhonghui Medical is still undergoing and the information of the fair values of the identifiable assets and liabilities is provisional at the date of the interim condensed consolidated financial information. The finalised information will be disclosed in the consolidated financial statements of the Group for the year ending 31 December 2024.

An analysis of the cash flows in respect of the acquisition of a subsidiary is as follows:

### 17. 業務合併(續)

中惠醫療的可識別資產及負債之公平值評估仍在進行中，於中期簡明綜合財務資料日期，可識別資產及負債之公平值資料為臨時資料。最終資料將於本集團截至2024年12月31日止年度之綜合財務報表中披露。

有關收購一間附屬公司的現金流量分析如下：

		RMB'000 人民幣千元 (Unaudited) (未經審核)
Cash consideration	現金代價	(12,239)
Cash and bank balances acquired	所收購的現金及銀行結餘	267
Net outflow of cash and cash equivalents included in cash flows from investing activities	計入投資活動之現金流量的現金 及現金等價物流出淨額	(11,972)

### 18. COMMITMENTS

At the end of each of the reporting period, the Group did not have any significant commitments.

### 18. 承擔

於各報告期末，本集團並無任何重大承擔。

# NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 未經審核中期簡明綜合財務資料附註

### 19. RELATED PARTY TRANSACTIONS

The Group's principal related parties are as follows:

### 19. 關聯方交易

本集團主要關聯方如下：

Company 公司	Relationship with the Company 與本公司的關係
Wellmark Link Limited 盈連有限公司	Shareholder 股東
WLF Investment Holdings Limited	Shareholder 股東
Ms. Wu Meirong 吳美容女士	Intermediate shareholder 中間股東
Mr. Wu Yushu 吳鬱抒先生	Director and key management personnel 董事及主要管理人員
Ms. Wang Lifang 王莉芳女士	Director and key management personnel 董事及主要管理人員
Mr. Fu Haitao 付海濤先生	Non-executive director and key management personnel 非執行董事及主要管理人員
Ms. Yi Xuhui 易旭暉女士	Key management personnel 主要管理人員
Mr. Tang Keke* 唐珂軻先生*	Key management personnel 主要管理人員
Mr. Su Caihua 蘇才華先生	Key management personnel 主要管理人員
Mr. Li Junguo 李俊國先生	Key management personnel 主要管理人員
Zhonghui Medical** 中惠醫療**	An entity influenced significantly by a director, Mr. Wu Yushu 受董事吳鬱抒先生重大影響的實體
Guangzhou Yishutong Technology Company Limited 廣州易數通科技有限公司	An entity influenced significantly by a director, Mr. Wu Yushu 受董事吳鬱抒先生重大影響的實體
Guangzhou Runer Ophthalmic Biotechnology Company Limited 廣州潤爾眼科生物科技有限公司	An entity influenced significantly by a shareholder, Ms. Wu Meirong 受股東吳美容女士重大影響的實體

\* Mr. Tang Keke resigned as key management personnel on 4 May 2023.

\*\* Zhonghui Medical became a subsidiary of the Company on 3 April 2024.

\* 唐珂軻先生於2023年5月4日辭任主要管理人員。

\*\* 中惠醫療於2024年4月3日成為本公司的附屬公司。

74 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION  
未經審核中期簡明綜合財務資料附註19. RELATED PARTY TRANSACTIONS 19. 關聯方交易(續)  
(continued)

(a) The Group had the following transactions with related parties during the period:

(a) 期內本集團與關聯方之間有以下交易：

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Sales to related parties*:	向關聯方銷售*：		
Guangzhou Runer Ophthalmic Biotechnology Company Limited	廣州潤爾眼科生物 科技有限公司	132	94
Guangzhou Yishutong Technology Company Limited	廣州易數通科技 有限公司	—	59
Purchases of services from related parties**:	向關聯方 購買服務**：		
Guangzhou Yishutong Technology Company Limited	廣州易數通科技 有限公司	63	172
Zhonghui Medical	中惠醫療	319	619
Depreciation of right-of-use assets***:	使用權資產 折舊***：		
Ms. Wu Meirong	吳美容女士	291	285
Interest expense on lease liabilities***:	租賃負債的利息 開支***：		
Ms. Wu Meirong	吳美容女士	24	32

# NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 未經審核中期簡明綜合財務資料附註

### 19. RELATED PARTY TRANSACTIONS (continued)

#### (a) The Group had the following transactions with related parties during the period: (continued)

- \* The sales to the related parties were made according to the prices and terms mutually agreed between the parties.
- \*\* The purchases from the related parties were made according to the prices and terms mutually agreed between the parties.
- \*\*\* The depreciation of right-of-use assets and interest expense on lease liabilities relate to the leases of the offices from related party pursuant to the terms of the agreements signed between the Group and the related party.

#### (b) Outstanding balances with related parties:

		<b>30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元</b>	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Due from Ms. Wu Meirong	應收吳美容女士的款項	<b>124</b>	45
Due to Guangzhou Runer Ophthalmic Biotechnology Company Limited	應付廣州潤爾眼科生物 科技有限公司的款項	<b>67</b>	59
Due to Guangzhou Yishutong Technology Company Limited	應付廣州易數通科技 有限公司的款項	<b>63</b>	126
Due to Zhonghui Medical	應付中惠醫療的款項	—	247

The above amounts of due to/from the related parties were trade in nature, unsecured, interest-free and repayable on demand.

上述應付／應收關聯方的款項屬貿易性質、無抵押、不計息及按要求償還。

#### (a) 期內本集團與關聯方之間有以下交易：(續)

- \* 向關聯方銷售乃根據雙方共同協定的價格及條款作出。
- \*\* 向關聯方的購買乃根據雙方共同協定的價格及條款作出。
- \*\*\* 使用權資產折舊及租賃負債的利息開支乃關於根據本集團與關聯方簽訂的協議條款從關聯方租賃辦公室。

#### (b) 與關聯方的未償還結餘：

76 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION  
未經審核中期簡明綜合財務資料附註

19. RELATED PARTY TRANSACTIONS 19. 關聯方交易(續)  
(continued)

(c) Compensation of key management personnel of the Group:

(c) 本集團主要管理人員的薪酬：

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Salaries, allowances and benefits in kind	薪金、津貼及實物福利	2,121	1,543
Pension scheme contributions	退休金計劃供款	20	19
Total compensation paid to key management personnel	已付主要管理人員的薪酬總額	2,141	1,562

# NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 未經審核中期簡明綜合財務資料附註

### 20. FINANCIAL INSTRUMENTS BY CATEGORY

The carrying amounts of each of the categories of financial instruments as at 30 June 2024 and 31 December 2023 are as follows:

#### 30 June 2024 (Unaudited)

##### Financial assets

		Financial assets at fair value through profit or loss 按公平值計入損益的金融資產 RMB'000 人民幣千元	Financial assets at amortised cost 按攤銷成本列賬的金融資產 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
Trade and notes receivables	貿易應收款項及應收票據	—	97,830	97,830
Financial assets included in prepayments, other receivables and other assets	計入預付款項、其他應收款項及其他資產的金融資產	—	7,057	7,057
Financial assets at fair value through profit or loss	按公平值計入損益的金融資產	88,460	—	88,460
Due from a related party	應收一名關聯方款項	—	124	124
Time deposits	定期存款	—	546,358	546,358
Cash and cash equivalents	現金及現金等價物	—	23,764	23,764
<b>Total</b>	<b>總計</b>	<b>88,460</b>	<b>675,133</b>	<b>763,593</b>

### 20. 按類別劃分的金融工具

於2024年6月30日及2023年12月31日，各類金融工具的賬面值如下：

#### 2024年6月30日(未經審核)

##### 金融資產

		Financial assets at fair value through profit or loss 按公平值計入損益的金融資產 RMB'000 人民幣千元	Financial assets at amortised cost 按攤銷成本列賬的金融資產 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
Trade and notes receivables	貿易應收款項及應收票據	—	97,830	97,830
Financial assets included in prepayments, other receivables and other assets	計入預付款項、其他應收款項及其他資產的金融資產	—	7,057	7,057
Financial assets at fair value through profit or loss	按公平值計入損益的金融資產	88,460	—	88,460
Due from a related party	應收一名關聯方款項	—	124	124
Time deposits	定期存款	—	546,358	546,358
Cash and cash equivalents	現金及現金等價物	—	23,764	23,764
<b>Total</b>	<b>總計</b>	<b>88,460</b>	<b>675,133</b>	<b>763,593</b>

78 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION  
未經審核中期簡明綜合財務資料附註20. FINANCIAL INSTRUMENTS BY CATEGORY 20. 按類別劃分的金融工具(續)  
(continued)

30 June 2024 (Unaudited) (continued)

2024年6月30日(未經審核)(續)

Financial liabilities

金融負債

		Financial liabilities at amortised cost 按攤銷成本列賬的金融負債 RMB'000 人民幣千元
Trade payables	貿易應付款項	12,835
Financial liabilities included in other payables and accruals	計入其他應付款項及應計費用的金融負債	32,461
Due to related parties	應付關聯方款項	130
Lease liabilities	租賃負債	13,901
Total	總計	59,327

31 December 2023 (Audited)

2023年12月31日(經審核)

Financial assets

金融資產

		Financial assets at amortised cost 按攤銷成本列賬的金融資產 RMB'000 人民幣千元
Trade and notes receivables	貿易應收款項及應收票據	90,043
Financial assets included in prepayments, other receivables and other assets	計入預付款項、其他應收款項及其他資產的金融資產	7,812
Time deposits	定期存款	509,405
Due from a related party	應收一名關聯方款項	45
Cash and cash equivalents	現金及現金等價物	123,931
Total	總計	731,236

# NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 未經審核中期簡明綜合財務資料附註

### 20. FINANCIAL INSTRUMENTS BY CATEGORY (continued)

31 December 2023 (Audited) (continued)

Financial liabilities

### 20. 按類別劃分的金融工具(續)

2023年12月31日(經審核)(續)

金融負債

		Financial liabilities at amortised cost 按攤銷成本列賬的金融負債 RMB'000 人民幣千元
Trade payables	貿易應付款項	13,109
Financial liabilities included in other payables and accruals	計入其他應付款項及應計費用的金融負債	3,966
Due to related parties	應付關聯方款項	432
Lease liabilities	租賃負債	14,237
<b>Total</b>	<b>總計</b>	<b>31,744</b>

### 21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

Management has assessed that the fair values of cash and cash equivalents, trade and notes receivables, trade payables, financial assets included in prepayments, other receivables and other assets, amounts due from a related party, financial liabilities included in other payables and accruals, the current portion of lease liabilities and amounts due to related parties approximate to their carrying amounts largely due to the short term maturities of these instruments.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

### 21. 金融工具公平值及公平值層級

據管理層評估，現金及現金等價物、貿易應收款項及應收票據、貿易應付款項、計入預付款項、其他應收款項及其他資產的金融資產、應收一名關聯方款項、計入其他應付款項及應計費用的金融負債、租賃負債流動部分及應付關聯方款項之公平值與其賬面值相若，乃主要由於該等工具到期日較短所致。

金融資產及負債的公平值以自願交易方(強迫或清盤出售除外)當前交易中該工具之可交易金額入賬。



80 NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION  
未經審核中期簡明綜合財務資料附註**21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)**

The fair values of the non-current portion of lease liabilities has been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities. The changes in fair value as a result of the Group's own non-performance risk for lease liabilities as at the end of the reporting period were assessed to be insignificant.

The Group invests in unlisted investments, which represent certain financial products issued by commercial banks and a wealth management product issued by a portfolio company in Chinese Mainland. The Group has estimated the fair value of these unlisted investments by using a discounted cash flow the valuation model based on the market interest rates of instruments with similar terms and risks.

The fair value of unlisted equity investment at fair value through profit or loss has been estimated using the discounted cash flow method based on assumptions that are not supported by observable market prices or rates. The directors believe that the estimated fair value resulting from the valuation technique, which is recorded in the consolidated statement of financial position, and the related change in fair values, which is recorded in the profit and loss, are reasonable, and that they were the most appropriate values at the end of the reporting period.

**21. 金融工具公平值及公平值層級 (續)**

租賃負債非流動部分的公平值已按使用擁有類似條款、信貸風險及餘下年期之工具現時可用比率貼現之預期未來現金流量計算。於報告期末，本集團本身就租賃負債的不履約風險產生的公平值變動被評估為不重大。

本集團投資於非掛牌投資，該等投資指中國內地商業銀行發行的若干金融產品及產品組合公司上市的一款理財產品。本集團根據具有類似條款及風險的工具的市場利率，使用貼現現金流量估值模型估計該等非掛牌投資的公平值。

按公平值計入損益的非上市股權投資的公平值乃使用貼現現金流量法估計，該方法所依據的假設為並無可觀察的市場價格或費率支持。董事認為，由估值技術所得的估計公平值(列入綜合財務狀況表)及有關公平值變動(列入損益)屬合理且為報告期末最適當的價值。

# NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 未經審核中期簡明綜合財務資料附註

### 21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

#### Assets measured at fair value:

30 June 2024 (Unaudited)

### 21. 金融工具公平值及公平值層級 (續)

下表列示本集團金融工具之公平值計量層級：

#### 按公平值計量的資產：

2024年6月30日(未經審核)

		Fair value measurement using 使用以下方式的公平值計量			
		Quoted prices in active markets 於活躍市場 的報價 (Level 1) (第1級) (unaudited) (未經審核) RMB'000 人民幣千元	Significant observable inputs 重大可觀察 輸入數據 (Level 2) (第2級) (unaudited) (未經審核) RMB'000 人民幣千元	Significant unobservable inputs 重大不可觀 察輸入數據 (Level 3) (第3級) (unaudited) (未經審核) RMB'000 人民幣千元	Total 總計 (unaudited) (未經審核) RMB'000 人民幣千元
Financial assets at fair value through profit or loss	按公平值計入損益的 金融資產	—	79,633	8,827	88,460

The Group did not have any financial assets measured at fair value as at 31 December 2023.

於2023年12月31日，本集團並無按公平值計量之金融資產。

The Group did not have any financial liabilities measured at fair value as at 30 June 2024 (31 December 2023: Nil).

於2024年6月30日，本集團並無任何按公平值計量的金融負債（2023年12月31日：無）。

During the reporting period, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 for both financial assets and financial liabilities.

於報告期間，就金融資產及金融負債而言，第1級與第2級之間並無公平值計量轉移，亦無轉入或轉出第3級。

## 82 DEFINITIONS

## 釋義

“AI”		artificial intelligence
「AI」	指	人工智能
“AI-MDT”		artificial intelligence multi-disciplinary treatment
「AI-MDT」	指	人工智能多學科治療
“Articles of Association”		the articles of association of the Company (as amended from time to time)
「組織章程細則」	指	本公司的組織章程細則(經不時修訂)
“Audit Committee”		the audit committee of the Board
「審核委員會」	指	董事會下設的審核委員會
“Board”		the board of Directors
「董事會」	指	董事會
“B2C”		Business-to-Customer, sell products and services directly to consumers
「B2C」	指	Business-to-Customer，直接面向消費者銷售產品和服務
“CG Code”		the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
「企業管治守則」	指	上市規則附錄C1所載企業管治守則
“China” or “PRC”		the People's Republic of China, but for the purpose of this report only and except where the context requires otherwise, references in this report to “China” or “PRC” do not include Hong Kong, the Macau Special Administrative Region and Taiwan
「中國」	指	中華人民共和國，但僅就本報告而言及另外按文義所需，凡在本報告內提述「中國」，均不包括香港、澳門特別行政區及台灣
“CHIS”		Chinese Health Industry Intelligence Information System, one of the Group's SaaS products that provides customers with industry information inquiry, retail data inquiry, drug database and other functions
「開思」	指	中國健康產業智能情報系統，本集團智慧決策雲一款SaaS產品，為客戶提供行業資訊查詢、零售端數據查詢、藥品數據庫等功能
“connected person(s)”		has the meaning ascribed to it in the Listing Rules
「關連人士」	指	上市規則賦予的涵義

“CPEO”		Health Industry Ecological Conference, China's health industry forward-looking ecological conference
「西普會」	指	健康產業生態大會，中國健康產業前瞻性的生態會議
“CPIE”		Pharmaceutical Innovation Ecosystems Conference, a forward-looking ecological conference on pharmaceutical innovation in China
「西派會」	指	醫藥創新生態大會，中國醫藥創新領域前瞻性的生態會議
“Company”		Sinohealth Holdings Limited, an exempted company with limited liability incorporated in the Cayman Islands on 4 March 2019 and registered as a non-Hong Kong company under Part 16 of the Companies Ordinance on 7 July 2021
「本公司」	指	中康控股有限公司，一家於2019年3月4日在開曼群島註冊成立的獲豁免有限公司，並根據公司條例第16部於2021年7月7日註冊為非香港公司
“Contractual Arrangements”		the series of contractual arrangements entered into by Zhongkang Technology, Sinohealth Information and its subsidiaries, the VIE Shareholders and the Other VIE Shareholders, as applicable, on 8 June 2021 and 6 May 2022, the details of which are described in the section headed “Contractual Arrangements” in the Company prospectus
「合約安排」	指	由中康科技、中康資訊及其附屬公司、可變利益實體股東及其他可變利益實體股東(如適用)於2021年6月8日及2022年5月6日訂立的一系列合約安排，有關詳情請參閱本公司招股章程「合約安排」一節
“CRO”		Contract Research Organization, an academic or commercial scientific institution that provides specialized services in the research and development process of basic medicine and clinical medicine for pharmaceutical enterprises, medical institutions, small and medium-sized medical device R&D enterprises and other institutions through contract
「合同研究組織」	指	合同研究組織，通過合同形式為制藥企業、醫療機構、中小醫藥醫療器械研發企業等機構在基礎醫學和臨床醫學研發過程中提供專業化服務的一種學術性或商業性的科學機構
“Director(s)”		the director(s) of the Company
「董事」	指	本公司董事

## 84 DEFINITIONS

## 釋義

“Eligible Participant”		any individual being an Employee Participant, Related Entity Participant or Service Provider, provided such person is not a connected person of the Group
「合資格參與者」	指	任何僱員參與者、相關實體參與者或服務供應商的個人，但該人士並非本集團的關連人士
“FY2022”		financial year ended December 31, 2022
「2022財年」	指	截至2022年12月31日的財政年度
“FY2023”		financial year ended December 31, 2023
「2023財年」	指	截至2023年12月31日的財政年度
“Global Offering”		the Hong Kong public offering and international offering of the Shares
「全球發售」	指	股份的香港公开发售及國際發售
“Group” or “We”		the Company and its subsidiaries
「本集團」或「我們」	指	本公司及其附屬公司
“HK\$”		Hong Kong dollars, the lawful currency of Hong Kong
「港元」	指	香港法定貨幣港元
“HKFRS”		Hong Kong Financial Reporting Standards issued by the Hong Kong Institute of Certified Public Accountants
「香港財務報告準則」	指	香港會計師公會頒佈的香港財務報告準則
“Hong Kong”		the Hong Kong Special Administrative Region of the PRC
「香港」	指	中國香港特別行政區
“ISO”		International Organization for Standardization
「ISO」	指	國際標準化組織
“Listing Date”		12 July 2022, on which the Shares were listed on the Stock Exchange and from which dealings in the Shares were permitted to commence on the Stock Exchange
「上市日期」	指	2022年7月12日，即股份在聯交所上市及股份獲准自該日起開始在聯交所買賣的日期
“Listing Rules”		the Rules Governing the Listing of Securities on the Stock Exchange
「上市規則」	指	聯交所證券上市規則

“MASC”		Health Traffic Conference, our conference platform focused on traffic research and value interaction
「美思會」	指	健康領域流量大會，我們舉辦的專注於流量研究及價值交互的會議平台
“Model Code”		Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules
「標準守則」	指	上市規則附錄C3所載上市發行人董事進行證券交易的標準守則
“Nomination Committee”		the nomination committee of the Board
「提名委員會」	指	董事會下設的提名委員會
“O2O”		Online To Offline, a form of transaction in which goods or services are booked or placed online and delivered offline
「O2O」	指	商品或者服務線上預訂或下單，線下完成交付的一種交易形式
“PHCF”		Pharma & Healthcare Conference and Fair, our event held for healthcare industry players
「西鼎會」	指	健康商品交易大會，我們為健康產業參與者舉辦的活動
“Prospectus”		prospectus of the Company dated 28 June 2022 in connection with the Global Offering
「招股章程」	指	本公司日期為2022年6月28日有關全球發售的招股章程
“Remuneration Committee”		the remuneration committee of the Board
「薪酬委員會」	指	董事會下設的薪酬委員會
“Reporting Period”		Six months ended 30 June 2024
「報告期」	指	截至2024年6月30日止六個月
“RMB”		Renminbi, the lawful currency of China
「人民幣」	指	中國法定貨幣人民幣
“SaaS”		software as a service, a cloud-based software licensing and delivery model in which software and associated data are centrally hosted
「SaaS」	指	軟件即服務，一種雲端軟件授權及交付模式，軟件及相關數據可在其中集中存儲

## 86 DEFINITIONS

## 釋義

“SCRM”		Social Customer Relationship Management, engaging with customers through social media and using technology to disseminate, capture and analyze customer data to discover customer needs and maintain long-term customer relationships. More emphasis on customer engagement and two-way interaction than traditional customer relationship management
「社交型客戶關係管理」	指	社交型客戶關係管理，通過社交媒體與客戶互動，利用技術手段傳播、獲取和分析客戶數據，以發掘客戶需求並維持長期的客戶關係。較傳統客戶關係管理強調客戶參與和雙向互動
“SFO”		the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
「證券及期貨條例」	指	香港法例第571章證券及期貨條例
“Share Option Scheme”		the share option scheme adopted by the Company on 27 April 2022
「購股權計劃」	指	本公司於2022年4月27日採納的購股權計劃
“Share Award Scheme”		the share award scheme adopted by the Company on 5 December 2022
「股份獎勵計劃」	指	本公司於2022年12月5日採納的股份獎勵計劃
“Share(s)”		ordinary share(s) of nominal value of HK\$0.01 each in the share capital of the Company
「股份」	指	本公司股本中每股面值0.01港元的普通股
“Shareholder(s)”		holder(s) of the Share(s)
「股東」	指	股份持有人
“SIC”		One of SaaS products of the Group's Smart Retail Cloud business segment, that provide pharmacies with comprehensive services such as operation management, membership management, category management, smart marketing, chronic disease management and pharmaceutical services
「SIC」	指	本集團智慧零售雲業務版塊一款SaaS產品，為藥店提供經營管理、會員管理、品類管理、智能營銷、慢病管理、藥事服務等綜合性服務

“Sinohealth Information”		Guangzhou Sinohealth Information Co., Ltd (廣州中康資訊股份有限公司), a joint stock company with limited liability established in the PRC on 20 December 2007 and deemed to be a wholly-owned subsidiary of the Group pursuant to the Contractual Arrangements
「中康資訊」	指	廣州中康資訊股份有限公司，一家於2007年12月20日在中國成立的股份有限公司，根據合約安排被視為本集團的全資附屬公司
“Stock Exchange”		The Stock Exchange of Hong Kong Limited
「聯交所」	指	香港聯合交易所有限公司
“tertiary hospitals”		tertiary-grade A class hospitals, which belong to the highest level in the classification of hospitals pursuant to the classification of medical institutions in accordance with China’s existing Hospital Classification Management Measures and other regulations
「三甲醫院」	指	全稱三級甲等醫院，依照中國現行《醫院分級管理辦法》等的規定劃分的醫療機構級別，是醫院等級劃分中的最高級別
“TMEC”		The whole industry chain ecological conference we held for the Chinese medicine market segment
「中醫藥生態大會」	指	我們針對中醫藥細分市場舉辦的全產業鏈生態大會
“To B Business”		Sell products and services directly to pharmaceutical and medical equipment enterprises, pharmaceutical retail enterprises
「To B 業務」	指	直接面向制藥及醫療設備企業、醫藥零售企業提供銷售產品和服務
“To C Business”		Sell products and services directly to consumers
「To C 業務」	指	直接面向消費者銷售產品和服務
“To R Business”		Sell products and services directly to relevant entities in the field of biomedical research and development
「To R 業務」	指	直接面向生物醫藥研發領域的相關主體銷售產品和服務
“Top List of the Most Promising Artificial Intelligence Enterprises in Guangzhou”		the top list of the most promising artificial intelligence enterprises in Guangzhou under the guidance of Guangzhou Science and Technology Bureau and selected by Guangzhou Technology Financial Group
「廣州最具發展潛力人工智能企業榜單」	指	在廣州市科學技術局指導及由廣州科技金融集團評選的廣州最具發展潛力人工智慧企業榜單



## 88 DEFINITIONS

## 釋義

“Trust”		the trust constituted by the Trust Deed
「信託」	指	由信託契據構成的信託
“Trustee”		Futu Trustee Limited, a professional trustee appointed under the Trust Deed to act as trustee of the Trust
「受託人」	指	富途信託有限公司，根據信託契據被任命為信託受託人的專業受託人
“US\$”		United States dollars, the lawful currency of the United States of America
「美元」	指	美國法定貨幣美元
“VIE Shareholders”		Mr. Wu Yushu and Ms. Wang Lifang, being the registered shareholders of Sinohealth Information
「可變利益實體股東」	指	吳鬱抒先生及王莉芳女士，即中康資訊的登記股東
“Zhonghui Medical”		Guangzhou Zhonghui Medical Technology Company Limited (廣州中惠醫療科技有限公司), a limited liability company established in the PRC on 28 December 2021, On February 5, 2024, Zhonghui Medical was acquired 50.6% of the equity by Zhongkang Information, a subsidiary of the Group, and became a related subsidiary of the Group at the issuer level
「中惠醫療」	指	廣州中惠醫療科技有限公司，一家於2021年12月28日在中國成立的有限責任公司，2024年2月5日由本集團附屬公司中康資訊一攬子收購50.6%的股權，成為本集團發行人層面的關連附屬企業
“Zhongkang Technology”		Guangzhou Zhongkang Digital Technology Co., Ltd. (廣州中康數字科技有限公司), a company established in the PRC with limited liability on 8 April 2019, which is directly owned as to 100% by Sinohealth Technology Limited, an indirect wholly-owned subsidiary of the Group
「中康科技」	指	廣州中康數字科技有限公司，一家於2019年4月8日在中國成立的有限公司，由中康健康科技有限公司直接持有100%權益，為本集團的間接全資附屬公司
“%”		Percent
「%」	指	百分比



*Sinohealth Hldg*  
中康控股

中康控股有限公司

Sinohealth Holdings Limited